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Introduction
Diabetes Mellitus (DM) is the most common metabolic disorder worldwide. The global 
incidence and prevalence of DM is rapidly increasing in both developed and developing 
countries, with the number of patients with DM expected to exceed 592 million world- 
wide by 2035 (1,2). The projected increase can be attributed to a combination of demo- 
graphic changes, the growing worldwide obesity epidemic and aging of the population 
growth (3,4). 
DM is associated with an excess in morbidity and mortality (5). Compared to patients 
without DM, people with diabetes are between two and four times more likely to have 
cardiovascular disease (CVD), with CVD accounting for a large proportion of the excess 
mortality related to diabetes(6-10). In fact, CVD accounts for 80% of all deaths and 75% 
of all hospital admissions in diabetic patients(11).  DM is an established and independent 
risk factor for coronary artery disease (CAD) and ischaemic stroke, and a diagnosis of DM 
is considered a CAD equivalent; given that diabetic patients without a history of CAD 
have a 5-year cardiovascular mortality similar to non-diabetic patients with a history of 
myocardial infarction (MI) (12,13). Furthermore, DM is associated with an excess in other 
coronary risk factors such as hypertension, dyslipidaemia, and obesity, which may additionally 
contribute to the worse outcomes associated with the condition(7). 
DM and revascularisation for coronary artery disease
As far back as the 1990’s, it was recognised that DM patients suffered from poorer outcomes 
with balloon angioplasty and percutaneous coronary intervention (PCI).  The BARI trial, 
which compared the safety and efficacy of coronary artery bypass grafting (CABG) and 
PCI in a randomized population of patients with multi-vessel disease, indicated that 
diabetic patients who underwent CABG had increased rates of 5 and 10-year survival and 
decreased rates of MI compared with those who underwent PCI and appeared to have 
improved medium to long-term survival rates with CABG(14,15). Indeed, one of the 
postulated mechanisms for this improved survival with CABG in DM patients, particularly 
amongst those who received internal mammary grafts, was that such treatment protected 
these patients from more rapid progression in PCI and untreated segments. In the 
intervening years, despite major advances in percutaneous coronary intervention (PCI) 
and the development of newer generations of drug-eluting stents and improvements in 
accompanying medical therapy, studies have continued to consistently show a trend 
toward more frequent major adverse cardiovascular and cerebrovascular events in 
patients with DM compared to non-DM patients(16). Whilst refinements in stent design 
have significantly improved outcomes in non-DM patients; with lower rates of target 
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vessel revascularisation, cardiac mortality and rates of stent thrombosis, such improvements 
have regrettably not been transferred to DM patients(17). 
Furthermore, despite advances in PCI treatment, the FREEDOM trial has now definitively 
shown that for DM patients with multi-vessel disease, CABG is a superior treatment and is 
associated with significantly lower rates of adverse cardiac events than treatment with 
PCI(18). Yet again, the more complete revascularisation provided by CABG compared to 
the more focal treatment garnered by PCI is associated with a more durable survival. Thus, 
further stent refinements may improve the outcomes in treated coronary segments of DM 
patients, however accelerated progression and vulnerability in untreated segments will 
continue to place DM patients at higher risk when treated with focal PCI. 
Therefore, the development of better risk stratification for DM patients, utilising intra- 
coronary assessments such as haemodynamic assessments of ischaemia and intra-coronary 
assessments of plaque morphology, may be our chance to finally “bridge the gap” for PCI.
Ischaemia and Fractional Flow Reserve
Undoubtedly in patients with coronary artery disease, the presence or absence of inducible 
myocardial ischaemia is the most important risk factor for adverse cardiac outcomes(19-21). 
Those patients with the largest extent of ischaemia are at the highest risk and derive the 
greatest benefit from revascularisation and patients with incomplete revascularisation 
and a large burden of residual ischaemia suffer the poorest outcomes(22). Alternatively, 
patients without ischaemia have much more benign outcomes. In this regard, the extent 
and severity of myocardial ischaemia can be used to predict outcomes and to risk-stratify 
patients. 
Fractional Flow Reserve (FFR) is presently the gold-standard intra-coronary invasive 
assessment of myocardial ischaemia(23). Multiple studies have proven that FFR is 
reproducible and has greater sensitivity than angiographic assessment and other non- 
invasive ischaemia tests in determining the functional relevance of coronary lesions, 
resulting in more selective revascularisation(24,25). Utilising an FFR-guided revascularisation 
strategy; revascularisation is performed only for ischaemic lesions, whilst it is deferred for 
those lesions which are non-ischaemic (FFR>0.80). Moreover, the outcome of residual 
coronary lesions which are haemodynamically non-significant is excellent, with an event 
rate of less than 1% per year and this is not improved by revascularisation(24,26-28). 
Finally, through the avoidance of unnecessary stent placement using such a strategy, 
significant cost reduction is noted(29). The incorporation of FFR into present day revascular-
isation strategies has resulted in substantial improvements over angiography guided re-
11
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vascularisation, and the use of FFR to improve and refine our treatment choices in DM 
patients is therefore appealing. 
Intracoronary imaging and the search for  
vulnerable plaque
Acute myocardial infarction (AMI) is typically a consequence of sudden and complete 
occlusion of a coronary artery by thrombus, usually occurring at the site of an atheroscle-
rotic lesion(30). Older angiographic studies have suggested that such AMI’s occur at the 
site of mild coronary artery stenoses, and angiographic assessments of lesion severity may 
be inadequate to accurately predict the time or location of a subsequent coronary 
occlusion that will produce a myocardial infarction(31,32). Furthermore, pathological 
studies have demonstrated the common association of AMI with the rupture or erosion of 
a plaque characterised by a large lipid or necrotic core separated from the lumen by a thin 
membrane cap, a so called thin-cap fibroatheroma (TCFA)(33-36). Thus, the identification 
of TCFAs and other features of so called “vulnerable plaque” has been the focus of recent 
investigation. Such studies have shown that TCFA typically occurs in lesions with relatively 
mild angiographic appearance and is most commonly observed in the proximal portion 
of each major coronary artery(33). Furthermore, these plaques are most often associated 
with positive vessel remodelling and this is likely the basis of the mild angiographic 
appearances(37). Nonetheless, continued outward expansion promotes neovascularisa-
tion of the plaque with eventual intra-plaque hemorrhage and thrombosis as a result of 
microvascular incompetence and immaturity(38). 
Although the presence of high-risk plaque such as TCFA’s signify rupture-prone lesions, 
more recently it has been recognised that such vulnerable plaques can often result in 
asymptomatic plaque rupture and healing and only occasionally leads to abrupt luminal 
obstruction and AMI. Nonetheless, repeated rupture (even asymptomatic) through the 
process of fibrotic healing, eventually results in a reduction in lumen size and presentation 
with stable angina for those patients. Therefore, the concept of the vulnerable patient, 
defined by high atherosclerotic burden, high-risk/vulnerable plaques and the presence of 
pro-thrombotic factors may explain why some plaques lead to clinical manifestations and 
AMI, whereas many others remain asymptomatic and heal. In this regard, DM patients 
could be considered the perfect prototypical vulnerable patient, characterised by a 
greater burden of atherosclerosis, hyperglycaemia induced endothelial dysfunction, 
increased platelet aggregation, and plaque instability(39-41). 
12
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Coronary artery disease burden and plaque 
composition in Diabetes Mellitus
Patients with DM express both a distinctly different pattern of disease and a higher burden 
of coronary plaque than those patients without DM(42). Atherosclerosis in DM tends to be 
more often diffuse, associated with longer lesion length, affects more often the distal 
coronary tree and left main stem and is associated with a higher prevalence of chronic 
total occlusions (43-45). Furthermore, multiple non-invasive imaging studies have 
repeatedly identified DM as being associated with a higher prevalence of coronary artery 
disease (CAD) than their non-DM counterparts(46-48). Based upon computed tomography 
angiography (CTA) studies, DM patients with non-obstructive CAD have significantly 
worse outcomes compared to those DM patients without atherosclerosis. Furthermore, 
outcomes in DM patients with 1-vessel obstructive disease and non-DM subjects with 
multi-vessel obstructive CAD are comparable(49). One possible explanation for this worse 
outcome even with non-obstructive CAD may be the aggressive and unremitting athero-
sclerosis progression which characterises the disease, which perhaps is as a result of more 
abundant high-risk plaque(50-52). 
In addition to a greater burden of atherosclerosis, significant phenotypic differences in 
plaque composition and morphology exist between patients with and without DM(52,53). 
Indeed, atheromatous plaques from DM patients display a greater number of lipid deposits 
and as a result of endothelial dysfunction, diabetic atherosclerosis is typically associated 
with negative remodelling resulting in a decrease in luminal size (44,54,55). Additionally, 
amongst those patients with acute coronary syndromes, culprit lesions are larger in 
DM patients, and show a greater abundance of plaque ulceration and thrombus 
presence(56,57). Moreover, multiple studies have demonstrated an accelerated and 
therapy refractory progression despite aggressive secondary prevention measures, 
including high-dose statins (44,51,58,59). Finally, intravascular studies have shown that 
high-risk vulnerable plaques, responsible for two-thirds of acute coronary syndromes 
(ACS) and sudden cardiac death and characterised by a dense infiltrate of macrophages 
and the presence of a large lipid pool with overlying thin fibrous cap (TCFA), are more 
prevalent in DM patients(53,60-62).
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Outline of the thesis
As described, DM patients have a higher prevalence, greater extent and more active 
metabolic substrate of atherosclerosis, and thus are often considered the highest-risk 
population. Therefore, this thesis examines whether intravascular imaging and haemo- 
dynamic assessments may provide additional insight with regards to the poorer outcomes 
seen in DM patients and whether the use of such tools may result in a refinement of our 
risk stratification in such patients. 
In the first instance, this thesis will specifically examine whether fractional flow reserve 
(FFR), the current reference gold standard invasive assessment of ischaemia is as reliable 
in DM patients. Specifically, I examine whether the absence of ischaemia as detected by 
FFR, results in a similar low-risk of future adverse cardiac events as seen in the general 
population. These research questions were assessed using data from a large cohort 
registry of patients undergoing FFR assessment in Isala Hartcentrum between 2010-2014. 
Secondly, the role of intravascular imaging techniques and the identification and 
consequences of high-risk plaque (TCFA) in DM patients was assessed by performing a 
sub-analysis of the PROSPECT (Providing Regional Observations to Study Predictors of 
Events in the Coronary Tree) study, a prospective natural history study of atherosclerosis, 
which used multimodality coronary imaging in patients at high risk for future cardiac 
events following intervention for ACS. 
In chapters 2, 3 and 4, the outcomes of a FFR-guided revascularisation strategy in DM 
patients is assessed. Traditionally, non-haemodynamically significant lesions (FFR >0.80) 
are associated with a low risk of future adverse events. However, to date the specific outcome 
of a FFR-guided revascularisation strategy in DM only patients has not been described. 
In chapter 2, I compare the outcomes of deferred revascularisation based upon a FFR 
>0.80 patients with and without DM. Chapter 3 examines the outcomes of a FFR guided 
strategy in patients with DM only, and specifically compares the outcomes of complete 
revascularisation of all FFR positive lesions versus deferred revascularisation of lesions 
FFR >0.80. Finally, chapter 4 assesses those factors which are associated with an increased 
risk of deferred lesion failure in DM patients with a FFR >0.80 and in addition examines 
whether the absolute FFR value (ranging from >0.80-1.00) may help to risk stratify DM 
patients with FFR negative lesions. 
In chapter 5, using data from a pre-specified sub-analysis of the PROSPECT study, the 
relationship between TCFAs, a vulnerable plaque marker, and subsequent major adverse 
cardiac events arising from medically treated non-culprit lesions in patients with acute 
coronary syndromes (ACS) with and without diabetes mellitus (DM) is investigated. 
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In chapter 6, the rationale and design of the COMBINE (OCT-FFR) study is described. In this 
study, and based in part upon the findings of FFR analyses in DM patients and the results 
of the PROSPECT study and sub-analyses, we will examine whether the addition of 
intra-vascular plaque morphological evaluation to FFR haemodynamic assessment of 
intermediate lesions in DM patients will better predict MACE and possibly lead to new 
revascularisation strategies. Finally, in chapter 7, based upon the above, the concept of 
whether ischaemia is the only clinically relevant factor in the prediction of cardiovascular 
outcomes in DM patients and if certain DM specific characteristics beyond ischaemia may 
need to be considered for a more refined risk stratification in these high-risk patients is 
reviewed. 
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Chapter 2
Abstract
Objective: Deferred revascularisation based upon fractional flow reserve (FFR >0.80), is 
associated with a low incidence of target lesion failure (TLF). Whether deferred revascular-
isation is also as safe in diabetes mellitus (DM) patients is unknown.
Methods: All DM patients and the next consecutive Non-DM patients that underwent an 
FFR-assessment between 1/01/2010 and 31/12/2013 were included, and followed until 
1/7/2015. Patients with only FFR>0.80 lesions were analysed according to the presence vs. 
absence of DM, while patients that underwent revascularisation in FFR-assessed or other 
lesions were excluded. The primary endpoint was the incidence of TLF; a composite of 
target lesion revascularisation (TLR) and target vessel myocardial infarction (TVMI). 
Results: A total of 250 patients (122 DM, 128 non-DM) who underwent deferred revascu-
larisation of all lesions (FFR>0.80) were compared. At a mean follow up of 39.8 ± 16.3 
months, DM patients compared to non-DM had a higher TLF rate, 18.1.% vs 7.5%, logrank 
p= <0.01, Cox regression-adjusted HR: 3.65 (95%CI:1.40-9.53, p<0.01), which was largely 
driven by a higher incidence of TLR (17.2% vs. 7.5%, HR: 3.52, 95%CI:1.34-9.30, p=0.01), whilst 
a non-significant but numerically higher incidence of TVMI (6.1% vs. 2.0%, HR: 3.34, 
95%CI:0.64-17.30, p=0.15) was observed.
Conclusions: This study, the largest to directly compare the clinical outcomes of 
FFR-guided deferred revascularisation in patients with and without DM, shows that DM 
patients are associated with a significantly higher TLF rate. Whether intravascular imaging, 
additional invasive haemodynamics or stringent risk factor modification may impact on 
this higher TLF rate remains unknown
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Introduction
Fractional flow reserve (FFR) has an established and extensive clinical evidence base, and 
represents now the gold-standard invasive functional assessment of coronary lesions. 
Compared to angiographic assessment alone, FFR guided revascularisation results in 
more judicious stent placement, with subsequent cost reduction and superior clinical 
outcomes[1-3]. Furthermore, based on landmark trials, deferred revascularisation in 
haemodynamic non-significant lesions (FFR >0.80) is associated with excellent clinical 
outcomes and low rates of major adverse cardiac events including target lesion revascu-
larisation (TLR) and myocardial infarction (MI)[1, 3]. 
However, longer-term data on deferred revascularisation primarily relates to patients with 
stable angina, with a low proportion of diabetes mellitus (DM) patients represented[1, 3]. 
DM patients have accelerated coronary atherosclerosis, an increased prevalence of micro-
circulatory dysfunction and a greater burden of high-risk plaque compared to non-DM 
patients[4-7]. Therefore, the medium to long-term outcomes of deferred revascularisation 
in high-risk populations with more rapidly progressive coronary atherosclerosis, such as 
patients with DM has not been thoroughly evaluated in previous studies. This particular 
study focuses on the clinical outcomes in patients with lesions which were non-haemo-
dynamically significant (FFR >0.80) and therefore were medically treated, in DM vs non-DM 
patients. 
Methods
Patient Population: In order to assess the safety and efficacy of FFR-guided deferred re-
vascularisation, from a total of 3,379 patients who underwent FFR-assessment from 
January 2010 until December 2013, we identified all DM patients as well as the next 
consecutive non-DM patients and followed these patients until 1/7/2015 (Figure 1). In 
order to avoid contamination of endpoints from events occurring from revascularised 
lesions, we further excluded all patients where a revascularisation took place in the FFR 
assessed and/or other lesions, so that only patients with FFR-negative lesions were 
included and further analysed. As shown in figure 1, the two groups analysed were: 
DM patients with FFR-negative lesions (FFR >0.80) where revascularisation was deferred 
[FFR(-)DM] vs. non-DM patients with FFR-negative lesions patients where revascularisation 
was deferred [FFR(-)NonDM]. 
Baseline demographics were obtained utilising electronic medical records, as was data 
relating to the FFR measurement and baseline angiography.  Follow up events were 
obtained primarily from the electronic patient record and by telephone contact with 
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primary care physicians or direct contact with patients where required. Follow up was 
complete in all FFR-assessed patients. FFR assessment was systematically performed in 
patients with intermediate native coronary lesions ranging from 40-80% diameter stenosis, 
where no prior non-invasive test of ischaemia was performed or when these were 
inconclusive. FFR was not performed for culprit lesions in MI, lesions with TIMI flow <3, or 
when the operator deemed a lesion to be clearly of haemodynamic significance.
The FFR was performed using a standard coronary pressure wire (PressureWire Certus, 
St. Jude Medical or Combowire, Volcano Corp). As per standard protocol, intravenous 
adenosine was infused at a rate of 140μg/kg/min to achieve maximum hyperaemia. 
Both baseline FFR and maximum hyperaemic FFR values were noted for each lesion. 
After steady-state hyperaemia was achieved, the FFR was calculated as the ratio of mean 
distal intracoronary pressure measured by the pressure wire, and the mean arterial 
pressure measured through the coronary guiding catheter. In situations where multiple 
FFR measurements of a lesion were made, the lowest measurement was used as the final 
assessment. A cut-off value of >0.80 was taken to imply a functionally non-significant 
coronary stenosis and the patient underwent deferred revascularisation and continued 
guideline directed medical therapy. 
Visual assessment of reference vessel diameter, diameter stenosis, American Heart 
Association/American Cardiology College (AHA/ACC) lesion type and the presence of 
calcification and diffuse disease were noted for all lesions by two independent inter- 
ventional cardiologists. Both reviewers were blinded to the clinical outcomes. A third 
interventional cardiologist was used in cases where discordance arose. In addition, the 
Syntax Score (SS) was calculated, based upon the index (time of FFR-measurement) 
coronary angiogram, by scoring all lesions >1.5mm with at least 50% diameter stenosis[8]. 
For those patients with a prior coronary artery bypass graft (CABG), no SS was calculated. 
The local Institutional Review Board approved this study and waived the requirement 
for written consent to an institutional registry. 
Endpoints and Definitions: Diabetes Mellitus was defined by patient history and 
classified by treatment with diet, exercise, oral anti-diabetic medication or insulin. The 
primary endpoint was the incidence of Target Lesion Failure (TLF), defined as a composite 
of target lesion revascularisation (TLR) and target vessel myocardial infarction (TVMI). 
Target lesion was defined as the lesion(s) in which the FFR measurement was performed, 
with TLR referring to revascularisation in that lesion(s). Myocardial Infarction was defined 
according to established guidelines[9]. Target vessel myocardial infarction (TVMI) refers to 
the occurrence of myocardial infarction within the vessel in which the FFR was assessed. 
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Statistical Methods: Continuous variables are summarised as mean ± standard deviation. 
Discrete variables are summarised as frequency (group percentage). Group comparisons 
were tested using Student’s t-test or Mann-Whitney U test for continuous variables and 
Pearson’s x2 test for discrete data. Kaplan-Meier estimates were used to estimate survival 
curves, and the log-rank test was used to establish differences between groups. Cox 
proportional hazards multiple regression models were used to estimate differences in time to 
event between the two groups expressed as hazard ratio’s (HR) with 95% confidence 
intervals, adjusted for several patient characteristics. In the exploratory model; gender, 
age, renal insufficiency, hypertension, hypercholesterolaemia, prior MI, prior PCI, prior CABG, 
smoking, reference vessel diameter, diameter stenosis, the presence of calcific and diffuse 
disease, and the absolute hyperaemic FFR value were analysed. A p value of <0.05 was 
considered significant. All analyses were conducted using SPSS 23 (SPSS Inc., Chicago, IL, USA). 
Results
Baseline characteristics: As shown in Figure 1, a total of 588 patients who underwent 
FFR assessment and fulfilled enrolment criteria were analysed, of which 250 patients 
(329 lesions) had only lesions with an FFR >0.80 and were further treated medically. 
Of these, 122 patients (157 lesions) and 128 patients (172 lesions) formed the FFR(-)DM 
group and FFR(-)NonDM groups respectively. The mean length of follow up was 39.8 
± 16.3 months (±SD).  
Baseline clinical and angiographic characteristics are noted in Table 1. The average age 
of patients was 67.6 ± 10.2  years, however patients were older  (70.4 ± 9 vs. 65.0 ± 10.7, 
p<0.01) in the FFR(-)DM group. Overall, the baseline characteristics were well matched in 
both groups, however more patients had hypertension (95.9% vs. 80.5%, p<0.01), renal 
insufficiency (16.4% vs. 1.6%, p<0.01) and prior CABG (17.2% vs. 7.8%, p=0.02) in the FFR(-)
DM group. Both the mean Syntax Score (SS) (8.71 ± 6.43 vs. 8.68 ± 5.46, p=0.75) and the 
mean FFR result (0.88 ± 0.05 vs. 0.88 ±0.05, p=0.24) was similar in both groups. Within the 
FFR(-)DM group, the mean HbA1c was 52.6 ± 9.1 mmol/mol.
As shown in Table 2, American Heart Association/American Cardiology College (AHA/
ACC) lesion type A was more frequent in the FFR(-)NonDM group (lesion level; 23.8% vs. 
14.6%, p=0.02), whilst lesion types B2 and C were more common in the FFR(-)DM group, 
(34.4% vs. 22.1%). Furthermore, patients with DM had more diffuse disease (22.3% vs. 11%, 
p=0.03). However, in both groups calcified lesions were similarly observed (19.7% vs. 18.6%, 
p=0.94) and both the reference vessel diameter (2.98 ± 0.45 vs. 3.02 ± 0.44, p=0.41) and 
percentage diameter stenosis (58.8% ± 8.3 vs. 59.1% ± 7.0, p=0.47) were similar in the FFR(-)
DM and FFR(-)NonDM groups respectively. 
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Clinical outcomes: The results of the clinical outcomes are shown in Table 3 and Figures 
2-4 by means of Kaplan-Meier curves. The primary outcome, TLF, was observed more 
frequently in the FFR(-)DM group, (18.1% vs. 7.5%, log-rank p<0.01), Cox-regression adjusted 
HR 3.65 (95% CI: 1.40-9.53, p<0.01), Figure 2. In addition the occurrence of TLR was 
significantly higher in the FFR(-)DM group, adjusted HR; 3.52 (95% CI: 1.34-9.30), p=0.01, 
Figure 3. In the DM group, 11/16 TLR events were as a result of TVMI or positive repeat 
FFR/ischaemic detection. The remaining 5/16 events were due to clear angiographic 
progression or unstable angina pectoris at presentation. A similar HR; 3.34 (95% CI: 
0.64-17.3), (p=0.15), Table 3, Figure 4, was also observed for TVMI, however due to lack of 
power, statistical significance was not reached but the trend is clear. Amongst those DM 
patients with TLF, HbA1c was higher (57.3 ± 14.4 vs. 51.8 ± 7.7 mmol/mol), however this did 
not reach statistical significance (p=0.10).
Figure 1   Study-flow chart. 
FFR denotes Fractional Flow Reserve; DM denotes Diabetes Mellitus.
3,379 Patients undergoing FFR-guided revascularisation
1/1/2010-31/12/2013
294 DM Patients
172 Patients excluded:
89 Patients-all lesions FFR ≤0.80 &
complete revascularisation
83 Patients- with ≥1 lesion(s) FFR
≤0.80 & underwent
revascularisation
FFR(-)DM group
All Lesions FFR>0.80
n=122
FFR(-)NonDM group
All Lesions FFR>0.80
n=128
166 Patients excluded:
76 Patients with all lesions FFR
≤0.80 & complete revascularisation
78 Patients with ≥1 lesion(s) FFR
≤0.80 & underwent
revascularisation
12 Patients missing follow-up
& next consecutive 294 Non-DM Patients
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Table 1  Baseline clinical characteristics
 
  FFR-DM FFR-NonDM p-value
n=122 n=128
Age, years, mean ± SD 70.4 ± 9.0 65.0 ± 10.7 <0.01
Gender, male, % (n) 59 (72) 62.5 (80) 0.57
Diabetes mellitus, % (n) 100 (122) 0 (0)
     Insulin-treated, % (n) 41.8 (51) 0 (0)
LV Ejection Fraction,  mean ± SD 52.8±10.6 51.8 ±10.6 0.73
Multi-vessel CAD, % (n) 24.6 (30) 29.7 (38) 0.56
Family history of CAD, % (n) 32.8 (40) 32.8 (42) 0.98
Hypertension, % (n) 95.9 (117) 80.5 (103) <0.01
Hypercholesterolaemia, n % (n) 95.9 (117) 93 (119) 0.31
Current smoking, % (n) 15.6 (19) 21.1 (27) 0.26
Renal Insufficiency, % (n) 16.4 (20) 1.6 (2) <0.01
Prior MI, % (n) 44.3 (54) 32 (41) 0.05
Prior PCI, % (n) 40.2 (49) 34.4 (44) 0.34
Prior CABG, % (n) 17.2 (21) 7.8 (10) 0.02
Table 2  Baseline Angiographic, FFR and Lesion characteristics
 
FFR-DM
N=122
FFR-NonDM
N=128
p-value
Syntax Score, mean ± SD 8.71 ±  6.43 8.68 ± 5.46 0.75
    Low Scores (0-22), % (n) 80.3 (98) 89.8 (115) 0.03
    Intermediate Scores (23-32), % (n) 0.8 (1) 1.6 (2) >0.99
    High Scores (≥33), % (n) 1.6 (2) 0.8 (1) 0.62
    Unclassified, prior CABG, % (n) 17.2 (21) 7.8 (10) 0.02
FFR performed in one lesion, % (n) 77 (94) 70.3 (90) 0.23
FFR performed in two lesions % (n) 17.2 (21) 25 (32) 0.13
FFR performed in three lesions, % (n) 5.7 (7) 4.7 (6) 0.71
FFR result, mean ±SD 0.88 ± 0.05 0.88 ± 0.05 0.24
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Table 2  Continued
 
Lesion Characteristics: At Lesion level n=157 n=172
AHA/ACC lesion type classification:
    Type A, % (n) 14.6 (23) 23.8 (41) 0.02
    Type B1, % (n) 51 (80) 54.1 (93) 0.91
    Type B2, % (n) 25.5 (40) 19.2 (33) 0.17
    Type C, % (n) 8.9 (14) 2.9 (5) 0.07
Calcified Lesion, % (n) 19.7 (31) 18.6 (32) 0.94
Diffuse Disease, % (n) 22.3 (35) 11 (19) 0.03
Reference Vessel Diameter†, mean ±SD (mm) 2.98 ± 0.45 3.02 ± 0.44 0.41
Percentage of Diameter Stenosis†, mean ± SD 58.79 ±8.3 59.07 ± 7.0 0.47
Table 3  Clinical Outcomes
 
  FFR(-)DM 
n=122
FFR(-)Non-DM
n=128
Adjusted HR 
(95% CI)
p-value
Target lesion Failure (TLF),  
% (n)
 18.1 (17) 7.5 (6) 3.65
(1.40-9.53)
<0.01
Target Lesion Revascularisation (TLR),  
% (n)
 17.2 (16) 7.5 (6) 3.52 
(1.34-9.30)
0.01
Target Vessel MI (TVMI),  
% (n)
6.1 (6) 2.0 (2) 3.34
(0.64-17.30)
0.15
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Figure 2   Time-to-event estimates for Target Lesion Failure according to FFR(-)DM and 
FFR(-)NonDM groups. 
TLF denotes Target Lesion Failure; CI denotes Confidence Interval; HR denotes Hazard Ratio (adjusted 
for age).
Figure 3   Time-to-event estimates for Target Lesion Revascularisation according to FFR(-)
DM and FFR(-)NonDM groups. 
TLR denotes Target Lesion Revascularisation; CI denotes Confidence Interval; HR denotes Hazard 
Ratio (adjusted for age).
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Discussion
The major finding of this analysis, the largest to date to directly compare the real-world 
clinical outcomes of haemodynamically non-significant (FFR>0.80) lesions which were 
treated medically in patients with versus without DM, shows that DM patients have a 
significantly higher risk of medium to long-term TLF. The observed higher TLF incidence 
in DM patients was driven primarily by efficacy events (TLR), whilst a trend for safety (TVMI) 
events, which did not reach statistical significance, was observed. 
Presently FFR is the gold standard invasive assessment of intermediate coronary lesions, 
with an extensive data to support its use[1, 3, 10, 11]. The DEFER and FAME studies have 
shown that deferred revascularisation based on FFR guidance, is safe and associated with 
a favourable medium to long-term prognosis[1, 3]. However, in both these studies, a low 
proportion of DM patients were included. A 5-year rate of 8.9% deferred lesion revascular-
isation was noted in the DEFER study (FFR >0.75), whilst in the FAME study, the 2-year rate 
of TLR was 3.2% in FFR negative lesions, both findings being comparable to TLR rates in 
the low-risk non-DM patients in our study.  Similarly, the rates of MI observed in these 
studies (DEFER; 5-year MI rate 0% in deferred lesions and FAME; 0.2% 2-year MI rate in 
lesions >0.80) are similar to rates observed in the non-DM patients in our study. 
Figure 4   Time-to-event estimates for Target Vessel Myocardial Infarction according to 
FFR(-)DM and FFR(-)NonDM groups. 
TVMI denotes Target Vessel Myocardial Infarction; CI denotes Confidence Interval; HR denotes Hazard 
Ratio (adjusted for age).
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Moreover, since FAME and DEFER, several other real-world studies have indicated that the 
rate of TLR for deferred lesions may be higher than previously reported in randomised 
trials. Rieber et al reported in a group of 56 patients, 11 revascularisations over a 5-year 
period (TLR 10.7%)[12] and more recently, two larger studies, which included a proportion 
of patients with reduced LV function and also patients 1-7 days after ACS, have shown over 
a longer follow-up rates of TLR in deferred lesions of 20.6% (n=721, median follow up 48.7 
months) and a 3.8% rate of deferred lesion MI (n=721, mean follow up 4 +/- 2.3 years)[13, 
14]. To date only one small single-centre study has directly examined the outcomes of 
deferred revascularisation in 40 DM and 96 non-DM patients, and whilst no significant 
difference was noted in the primary endpoint in that study, a numerically higher TLR rate 
(14.3% vs. 8.8%) was noted over an average of 30months follow-up[15]. Our results in the 
higher risk DM group are again comparable to the findings of these studies. 
Recently, concerns regarding increased vascular resistance and reduced vasodilative 
capacity due to chronic hyperglycaemia in DM patients have been raised[16]. Data from 
prior non-invasive studies which have assessed the microcirculatory function in patients 
with and without DM, have shown that even in those DM patients without known 
coronary artery disease (CAD), the presence of an abnormal coronary flow reserve (CFR) is 
associated with poor outcomes, comparable to non-DM patients with known CAD[17]. 
Furthermore in the The Prediction of CK-MB RElease During Successful Stenting Correlating 
with Indicators of Microvascular ObstruCTion (PREDICT) trial, despite similar pre-PCI FFR 
values, DM patients compared to patients without, have lower CFR measurements[18]. 
In a study by Meuwissen et al, in patients undergoing combined FFR and CFR assessment, 
approximately 10% of intermediate lesions when assessed as FFR>0.75, have an abnormal 
CFR defined as <2.0 and furthermore van de Hoef et al, have recently shown that in those 
patients in whom a FFR>0.80 is associated with an abnormal CFR (<2.0), the clinical 
outcomes are significantly worse than in patients with intact microcirculation[19, 20]. 
Recently Lee et al[21], confirmed these findings, also showing that DM patients with low 
CFR and high index of microvascular resistance (IMR) have significantly elevated adverse 
cardiac event rates. Furthermore, whilst higher FFR values are associated with a lower 
incidence of adverse cardiac events in Non-DM patients with deferred revascularisation, it 
has recently been shown that FFR values do not differentiate future risk in DM patients[22]. 
As shown from these studies, FFR alone may be insufficient to ascertain the true 
haemodynamic significance of lesions in DM patients and therefore incorrectly lead to 
deferred revascularisation of lesions than may otherwise be associated with high adverse 
event rates. This may in part explain the results observed in the DM group in our study
Additionally, it is known that compared to non-DM patients, atherosclerosis in diabetic 
patients is more often diffuse, with longer lesion length and is associated with a tendency 
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toward negative vessel remodelling[4, 23]. Moreover, those DM patients in whom insulin 
treatment is required have even worse outcomes[24]. Indeed as seen in the sub-group 
analysis from the Providing Regional Observations to Study Predictors of Events in the 
Coronary Tree (PROSPECT) study; radiofrequency intravascular ultrasound assessed lesion 
length, plaque burden, necrotic core, and calcium content were significantly greater 
among non-culprit lesions in DM as compared to non-DM patients[25, 26]. Indeed, recent 
evidence suggests that increased levels of plasma bone morphogenetic protein-2 (BMP-2) 
levels are found in DM patients and correlate positively with increased plaque burden, 
plaque calcification and negatively correlate with lumen volume[27]. Similarly, optical 
coherence tomography (OCT) studies, have shown that compared to non-DM patients, 
non-culprit lesions in DM patients have a larger lipid index, and when associated with 
elevated HbA1c levels, thin-cap fibroatheroma (TCFA) and macrophage infiltration is 
frequently observed[7].  In addition, in a second sub-group analysis of DM patients from 
the PROSPECT study, non-culprit lesions in DM patients when associated with a TCFA have 
a five-fold increased MACE rate at 3 years, whilst those DM patients without TCFA had a 
3-year MACE rate comparable to non-DM patients[28]. Thus, as shown in the above 
mentioned studies, DM patients more frequently carry high-risk lesions, which due to 
faster progression are associated with higher adverse events, despite often being angio-
graphically mild and thus likely to be haemodynamically non-significant. Indeed, this may 
provide another plausible explanation for the findings of our analysis. 
From the above, FFR assessment in combination with complementary haemodynamics 
(CFR and IMR) and also intravascular imaging may result in a more accurate deferred revas-
cularisation and at the same time guide a more focused medical therapy strategy in DM 
patients. Previous studies have indicated that stringent risk factor modification in DM 
patients results in plaque atheroma volume regression similar to non-DM patients, and 
tighter glycaemic control can reduce the occurrence of recurrent ischaemic events[29-33]. 
Study Limitations
The present study is a single-centre, non-randomised, observational study and thus the 
results should be considered as hypothesis generating. Cox proportional hazards multiple 
regression models were used to correct for the baseline characteristics differences 
resulting from the lack of randomisation. Nonetheless, some residual confounding may 
persist despite a careful attempt to adjust for clinically relevant factors. In addition, the 
study took place in a region with a predominantly Caucasian population and data relating 
to race and ethnicity was not captured in the registry, which may impact on the general-
isability of our results. As was the case in the FAME II study, neither patients nor clinicians 
were blinded to the FFR result[11]. Therefore, knowledge of a prior borderline FFR 
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measurement may have influenced the subsequent rates of TLR, however considering the 
retrospective nature of this study this was unavoidable. Nonetheless, the majority of TLR 
occurred in the setting of a subsequent acute coronary syndrome and in those patients 
with unstable and stable angina pectoris, the majority of revascularisations only took 
place after repeat FFR assessment/ischaemic detection. The combined use of coronary 
microcirculation assessment using CFR/IMR was not performed and the morphological 
composition of lesions in our study was unknown and therefore their impact on our 
results cannot be accurately assessed.   
Finally, patients included in our study may be at higher risk than those enrolled in prior 
randomised trials, however we believe that our results are representative of the real world 
outcomes of FFR-guided deferred revascularisation in patients with and without DM. 
Conclusion
DM patients in which revascularisation was deferred based upon FFR assessment have a 
higher TLF rate compared to non-DM patients. Our results should be considered hypothesis 
generating and whether a combination of FFR with complementary haemodynamics 
(CFR and IMR) and intravascular imaging may result in a more accurate deferred revasculari-
sation needs to be studied in larger dedicated studies. 
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Abstract
To assess the safety and efficacy of deferred versus complete revascularisation using a 
Fractional Flow Reserve(FFR)-guided strategy in Diabetes Mellitus(DM) patients, we 
analysed all DM patients that underwent FFR-guided revascularisation between 1/1/2010-
31/12/ 2013. Patients were divided into two groups; those with ≥1 remaining FFR-negative 
(> 0.80) medically treated lesions [FFR(-)MT] and those with only FFR-positive lesions 
(≤ 0.80) undergoing complete revascularisation [FFR(+)CR], and were followed until 1/7/2015. 
The primary endpoint was the incidence of major adverse cardiovascular events (MACE); 
a composite of death, myocardial infarction (MI), target lesion (FFR-assessed) revascularisation 
(TLR) and rehospitalisation for acute coronary syndrome (ACS). A total of 294 patients, 
205 (69.7%) vs. 89 (30.3%) in FFR(-)MT and FFR(+)CR, respectively, were analysed. At a mean 
follow-up of 32.6 ± 18.1 months, FFR(-)MT was associated with higher MACE rate 44.0% 
vs 26.6%, logrank p=0.02, Cox regression-adjusted HR:2.01;(95%CI :1.21-3.33, p<0.01), 
and driven by both safety and efficacy endpoints: Death/MI, HR 2.02;(95%CI: 1.06-3.86, 
p=0.03), rehospitalisation for ACS, HR 2.06;(95%CI; 1.03-4.10, p=0.04) and TLR, HR 3.38;(95%CI: 
1.19-9.64, p=0.02). Prior MI was a strong effect modifier within the FFR(-)MT group (HR 
1.98;95%CI(1.26-3.13), p<0.01), whilst this was not the case in the FFR(+)CR group 
(HR 0.66;95%CI(0.27-1.62), p=0.37). Significant interaction for MACE was present between 
FFR groups and prior MI (P=0.03). In conclusion, in DM patients, particularly those with 
prior MI, deferred revascularisation is associated with poor medium term outcomes. 
Combining FFR with imaging modalities may be required to guide our treatment strategy 
in these high-risk, fast-progressing atherosclerosis patients. 
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Introduction
Fractional flow reserve (FFR) is presently the guideline recommended invasive ischaemic 
assessment of intermediate coronary lesions.1 However, despite proven superiority in primarily 
stable angina patients, a FFR-guided revascularisation strategy has been extrapolated to 
high-risk patient subgroups, without robust clinical evidence.2-4 Incomplete revascularisation 
is associated with worse outcomes compared to complete revascularisation, particularly 
in patients with Diabetes Mellitus (DM) and multi-vessel disease.5  Based upon Fractional 
flow reserve versus Angiography for Multivessel Evaluation (FAME I, II) and DEFER studies, 
the outcome of residual coronary lesions which are haemodynamically non-significant is 
excellent and not improved by revascularisation.2-4 However, the central premise of deferred 
revascularisation centers on the assumption that these lesions, which are FFR>0.80, will 
remain quiescent over the short to medium term. Unfortunately, DM is associated with 
greater atherosclerotic burden, accelerated and therapy refractive atherosclerosis and 
thus the longevity of a FFR>0.80 is unknown in a DM only population.6,7 To date a direct 
comparison of complete versus deferred revascularisation in DM patients using FFR has 
not been described. Therefore, in order to study the impact of deferred versus complete 
revascularisation based upon a FFR-guided strategy in all-comer DM patients, and in 
particular to study the longevity of a negative FFR in DM patients, we retrospectively 
analysed the outcomes of DM patients in our center, where FFR-guided revascularisation 
represents the standard of care. 
Methods
From a total of 3,379 patients who underwent FFR-guided revascularisation between 
1/1/10-31/12/13, we identified all consecutive DM patients and followed these patients 
until July 2015. All patients had a prior diagnosis of DM, defined by patient history and 
classified by treatment with diet, exercise, oral anti-diabetic medication or insulin.
Baseline demographics were obtained by means of the electronic patient record, in 
addition to data relating to the FFR measurement and baseline angiography.  Follow up 
events were obtained from the electronic patient record based upon subsequent clinical 
review, by telephone contact with primary care physicians and referring hospitals or direct 
contact with patients where required. Follow up was complete in all FFR-assessed patients.
FFR assessment was performed systematically in all patients with intermediate coronary 
lesions ranging from 40-80% diameter stenosis, where no prior non-invasive test of 
ischaemia was performed or when these were inconclusive. FFR was not performed for 
culprit lesions in MI, lesions with Thrombolysis in Myocardial Infarction (TIMI) flow <3, or 
when the operator deemed a lesion to be clearly of haemodynamic significance. 
38
Chapter 3
FFR was performed using a standard coronary pressure wire (PressureWire Certus, St. Jude 
Medical, St Paul, Minnesota; or Combowire, Volcano Corporation, Rancho Cordova, 
California).  Both baseline FFR and maximum hyperaemic FFR values were noted for each 
lesion. After steady-state hyperaemia was achieved, the FFR was calculated as the ratio of 
mean distal intracoronary pressure measured by the pressure wire, and the mean arterial 
pressure measured through the coronary guiding catheter. A cut-off value of ≤0.80 was 
taken to imply a functionally significant coronary stenosis and the patient underwent 
 revascularisation as appropriate. A lesion with an FFR value of >0.80, was adjudicated as 
a functionally non-significant leading to deferred revascularisation and further medical 
treatment.
Visual assessment of reference vessel diameter, diameter stenosis, American Heart Association 
(AHA) lesion type and the presence of calcification and diffuse disease were noted for all 
lesions by two independent interventional cardiologists. Both reviewers were blinded to 
the clinical outcomes. A third interventional cardiologist was used in cases where 
discordance arose. In addition, the Syntax Score (SS) was calculated retrospectively, based 
upon the index (time of FFR-measurement) coronary angiogram, by scoring all lesions 
>1.5mm with at least 50% diameter stenosis using the previously described algorithm.8 
For those patients with prior Coronary Artery Bypass Graft (CABG), no SS was calculated. 
In order to assess the safety and efficacy of deferred versus complete revascularisation 
using a FFR-guided strategy in DM patients and to assess the longevity of a negative FFR 
in DM patients, two groups were formed, according to the presence or absence of any 
remaining FFR negative lesions (>0.80). The first group comprised of patients in whom 
≥1 FFR negative lesion (>0.80) remained and were further treated medically [FFR(-)MT], 
whilst the second group included patients with only FFR positive lesions (≤0.80), which 
underwent complete angiographic and functional revascularisation [FFR(+)CR]. The local 
Institutional Review Board approved this study and waived the requirement for written 
consent to an institutional registry. 
The primary endpoint was the incidence of Major Adverse Cardiac Events (MACE) defined 
as a composite of death, myocardial infarction (MI), target lesion revascularisation (TLR) or 
rehospitalisation for acute coronary syndrome (ACS). A composite of death or MI, in 
addition to rehospitalisation for ACS represented the safety endpoints, while the efficacy 
endpoint was represented by TLR.  Data relating to mortality was obtained from the Dutch 
national civilians register. Target lesion was defined as the lesion(s) in which the FFR was 
performed, with TLR referring to revascularisation in that lesion(s) whether treated by index 
 revascularisation or by medical therapy.  Myocardial Infarction (MI) and peri-procedural MI 
were defined according to the established guidelines. Recent myocardial infarction was 
defined as occurring less than 6 months prior to the FFR assessment. Rehospitalisation for 
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ACS, refers to urgent presentation to the Emergency Department for MI or Unstable 
Angina Pectoris (UAP) requiring an unscheduled hospitalisation. Complete  revascularisation 
was defined as the absence of any remaining lesions with an FFR>0.80 and any remaining 
coronary lesions >50% diameter stenosis in a viable myocardial territory, as determined by 
the operator. 
Continuous variables are summarized as mean ± standard deviation. Discrete variables are 
summarized as frequency (group percentage). Group comparisons were tested using 
Student’s t-test or Mann-Whitney U test for continuous variables and Pearson’s x2 test for 
discrete data. Kaplan-Meier (KM) estimates were used to estimate survival curves and 
event rates, and the log-rank test was used to establish differences between groups. Cox 
proportional hazards multiple regression models were used to estimate differences in 
time to event between the two groups expressed as hazard ratio’s (HR) with 95% 
confidence intervals, adjusted for several patient characteristics. In the exploratory model; 
gender, age, renal insufficiency, prior MI, Prior PCI, type of DM, levels of HbA1c, smoking, 
reference vessel diameter, diameter stenosis, the presence of calcific and diffuse disease, 
FFR value, multi-vessel disease and left ventricular ejection fraction were analysed.  Formal 
interaction testing was performed to determine whether the presence of identified 
effect- modifiers influenced the relative risk for the occurrence of MACE in both groups. 
A p value of <0.05 was considered significant. All analyses were conducted using SPSS 23 
(SPSS Inc., Chicago, IL, USA).
Results
From a total of 3,379 patients who underwent FFR-guided revascularisation, we identified 
294 consecutive DM patients who had FFR measurement in 385 intermediate coronary 
lesions (Figure 1). A total of 205 patients with at least 1 remaining FFR >0.80 lesion formed 
the FFR(-)MT group, and 89 patients were included in the FFR(+)CR group, having had 
complete revascularisation of all lesions. The mean length of follow up was 32.6 ± 18.1 
months (±SD). Baseline clinical and angiographic characteristics are noted in Table 1 and 
Table 2 respectively. The average age of patients was 69.2 ± 9.8 years, which was similar in 
both groups. Overall, baseline characteristics were well matched in both groups, however 
there were more male patients (75.3% vs. 61%, p=0.02) and more current smokers (33.7% 
vs. 20%, p=0.01) in the FFR(+)CR group. Patients in the FFR(-)MT group had a lower mean 
Syntax Score (SS) compared to the FFR(+)CR group, (10.84 ± 6.96 vs. 17.34 ± 12.44, p=0.001). 
In the FFR(-)MT group, 122 patients had all lesions (157 lesions) assessed as FFR negative. 
A total of 83 patients had index revascularisation (27 patients with a lesion assessed by FFR 
as £0.80 and 54 patients with non-FFR guided revascularisation of another lesion(s)) in 
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addition to deferred revascularisation based upon an FFR >0.80 of at least one other 
lesion. This treatment included 77 patients undergoing PCI and 6 patients in whom CABG 
was performed. In the FFR(-)MT group, all lesions <0.80 were revascularised. In the FFR(+)
CR group, 88 (98.8%) patients (37 patients by CABG and 51 patients by PCI) underwent 
complete revascularisation at index of 104/105 FFR £0.80 lesions, with one patient (1 lesion) 
not receiving index revascularisation due to technically unsuccessful PCI (Figure 1).
The results of the clinical outcomes are shown in Table 3 and Figures 2 a-d. The primary 
endpoint was observed more frequently in the FFR(-)MT group, (76 (KM event rate=44.0%) 
vs. 20 (KM event rate=26.6%)), unadjusted p=0.03 and after adjustment by multi-variate 
Cox-regression; HR 2.01 (95%CI 1.21-3.33, p<0.01), Table 3 and Figure 2a. Both safety 
endpoints death and/or MI and rehospitalisation for ACS were significantly higher in the 
FFR(-)MT group, Table 3 and Figure 2b and c. Similarly, the efficacy endpoint, TLR was also 
higher in the FFR(-)MT group, Table 3 and Figure 2d. 
Table 1  Baseline clinical characteristics
 
FFR(-)MT FFR(+)CR p-value
n=205 n=89
Age (years) 69.7 ± 9.6 68.0 ± 10.2 0.23
Men 125 (61%) 67 (75%) 0.02
Diabetes mellitus 205 (100%) 89 (100%) NA
    Insulin-treated 87 (42%) 36 (40%) 0.75
Left ventricle ejection fraction 51.8 ± 10.2 49.6 ± 11.2 0.16
Multi-vessel coronary artery disease 115 (56%) 38 (43%) 0.04
Family history of coronary artery disease 61 (30%) 40.4 (36%) 0.07
Hypertension 197 (96%) 85 (96%) 0.76
Hypercholesterolaemia 198 (97%) 85 (97%) >0.99
Current smoker 41 (20%) 30 (34%) 0.01
Renal insufficiency 30 (15%) 15 (17%) 0.63
HbA1c 53.7 ± 10.5 52.8 ± 10.3 0.59
Prior myocardial infarction 93 (45%) 45 (51%) 0.41
Remote myocardial infarction 47 (23%) 20 (23%) 0.93
Recent myocardial infarction 46 (22%) 25 (28%) 0.30
Prior percutaneous coronary intervention 82 (40%) 46 (52%) 0.06
Prior coronary artery bypass graft 29 (14%) 15 (17%) 0.55
Renal Insufficiency was defined as an estimated glomerular filtration rate, eGFR<60mL/min
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The Cox-regression multivariate analysis (Table 4), did not identify prior MI as a predictor of 
MACE, however prior MI had a strong effect within the FFR(-)MT group (HR 1.98; 95% CI 
(1.26-3.13), p<0.01), whilst this was not the case in the FFR(+)CR group (HR 0.66; 95% CI 
(0.27-1.62), p=0.37). Indeed, a significant interaction for MACE was observed between FFR 
groups and prior MI (P=0.03), indicating that the MACE events were predominantly 
clustered in the subgroup of patients in the FFR(-)MT group with prior MI, whereas FFR(-)
MT patients without a prior MI had similar MACE rates as FFR(+)CR patients (Figure 3).
Table 2  Baseline angiographic, fractional flow reserve (FFR) and lesion characteristics
 
FFR(-)MT
n=205
FFR(+)CR
n=89
p-value
Clinical syndrome at time of FFR performance:
Acute coronary syndrome 73 (36%) 33 (37%) 0.81
Non-acute coronary syndrome* 132 (64%) 56 (63%) 0.81
Mean Syntax Score 10.84 ±  6.96 17.34 ± 12.44 <0.01
    Low scores (0-22) 165 (81%) 54 (61%) <0.01
    Intermediate scores (23-32) 7 (3%) 7 (8%) 0.13
    High scores (≥33) 4 (2%) 13 (15%) <0.01
    Unclassified, prior coronary artery bypass graft 29 (14%) 15 (17%) 0.55
FFR performed in one lesion 143 (70%) 76 (85%) 0.01
FFR performed in two lesions 49 (24%) 10 (11%) 0.01
FFR performed in three lesions 13 (6%) 3 (3%) 0.41
Mean FFR result 0.86 ± 0.06 0.73 ± 0.06 <0.01
Lesion characteristics: lesion level
Number of lesions assessed 280 105
AHA/ACC lesion type classification:
    Type A 33 (12%) 6 (6%) 0.04
    Type B1 150 (54%) 33 (31%) <0.01
    Type B2 79 (28%) 57 (54%) <0.01
    Type C 18 (6%) 9 (9%) 0.68
Calcified lesion 57 (20%) 51 (49%) <0.01
Diffuse disease 77 (28%) 51 (49%) <0.01
Reference vessel diameter (mm)† 2.94 ± 0.43 2.96 ± 0.42 0.58
Diameter stenosis (%)† 60.46 ±8.48 65.96 ± 9.09  <0.01
*Includes stable angina and patients undergoing staged FFR of non-culprit lesions following 
ACS >1month previously. †Visual assessment
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Table 3  Clinical Outcome Results 
 
FFR(-)MT 
n=205
FFR(+)CR 
n=89
FFR(-)MT 
KM Estimate
n=205
FFR(+)CR 
KM Estimate
n=89
Adjusted HR 
(95% CI)
Adjusted 
p-value
Major adverse 
cardiac event
76 (37%) 20 (23%) 44.0% 26.6% 2.01 
(1.21-3.33)
<0.01
Mortality 36 (18%) 11 (12%) 23.8% 14.8% 1.78 
(0.88-3.60)
0.11
Myocardial  
infarction
13 (6%) 3 (3%) 7.2% 3.5% 1.81 
(0.51-6.38)
0.36
Death or myocardial 
infarction
46 (22%) 13 (15%) 28.6% 16.9% 2.02 
(1.06-3.86)
0.03
Rehospitalisation 
for acute coronary 
syndrome
44 (22%) 10 (11%) 24.8% 12.2% 2.06 
(1.03-4.10) 0.04
Target lesion 
revascularisation
29 (14%) 4 (5%) 17.6% 8.2% 3.38 
(1.19-9.64)
0.02
Event-rates shown are absolute event rates. K-M denotes Kaplan-Meier event rate estimates.
Figure 2a
Figure 2a-d   Time-to-event estimates for (a) MACE, (b) Mortality or Myocardial Infarction, 
(c) Rehospitalisation for Acute Coronary Syndrome and (d) Target Lesion 
Revascularisation according to FFR(-)MT and FFR(+)CR groups.
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Figure 2b
Figure 2c
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Figure 2d
MACE denotes Major Adverse Cardiac Event; HR denotes Adjusted Hazard Ratio; CI denotes 
Confidence Interval; MI denotes Myocardial Infarction; ACS denotes Acute Coronary Syndrome; 
TLR denotes Target Lesion Revascularisation.
Table 4  Multivariate predictors for major adverse cardiac events 
 
HR (95% CI) p-value
FFR(-)MT vs. FFR(+)CR 2.01 (1.21-3.33) <0.01
Age (per 1-year increase) 1.03 (1.01-1.05) 0.02
Multi-vessel coronary artery disease 0.79 (0.52-1.19) 0.25
Prior myocardial infarction 1.14 (0.70-1.84) 0.61
Prior percutaneous coronary intervention 1.78 (1.09-2.92) 0.02
Current smoker 1.44 (0.85-2.42) 0.18
Diabetes mellitus insulin dependent 1.68 (1.12-2.53) 0.01
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Discussion
The major finding of this study is that in DM patients undergoing an FFR-guided revascularisa-
tion strategy, the presence of ≥1 remaining FFR negative lesion(s) is associated with a 
significantly increased risk of MACE, as compared to DM patients undergoing complete 
index revascularisation, despite the latter group having more advanced disease at baseline. 
These results are in contrast to prior reports, which indicated that deferred revascularisation 
based upon a FFR >0.80 is associated with a low risk of future MACE.2-4 This elevated MACE 
rate is driven by both safety endpoints; Death and/or MI and rehospitalisation for ACS as 
well as the efficacy endpoint of TLR.  
To date several studies have examined FFR-guided revascularisation, with powerful 
reassurance that deferred revascularisation in non-ischaemic lesions (FFR>0.80) is safe and 
associated with excellent outcomes, however specific outcomes in DM are unknown.2-4, 9 
The current study is the first to assess the impact of a deferred versus complete revascu-
Figure 3   Time-to-event estimates for MACE, in FFR(-)MT and FFR(+)CR groups according 
to presence or absence of prior MI
MACE denotes Major Adverse Cardiac Event; MI denotes Myocardial Infarction; FFR denotes 
Fractional Flow Reserve; HR denotes Adjusted Hazard Ratio.
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larisation using FFR in a DM-only population, and so the findings cannot be directly 
compared to prior studies. DM patients have a higher burden of coronary atherosclerosis 
compared to non-DM patients.6 Furthermore, atherosclerotic disease in diabetic patients 
is strongly associated with a tendency toward negative vessel remodelling and faster 
coronary atherosclerosis progression.10 In the Providing Regional Observations to Study 
Predictors of Events in the Coronary Tree (PROSPECT) study and the subsequent subgroup 
analysis, DM patients had a two-fold increase in non-culprit lesion MACE rates at 3 years, 
originating from lesions which were angiographically mild (diameter stenosis; median 
36.2% IQR [31.1, 44.2]) and thus likely to be non-ischaemic.11,12 Similarly, in the the Diabetes 
and Sirolimus-Eluting Stent (DIABETES) trial, at 2-years, approximately 10% of patients 
required revascularisation in a vessel or segment remote from that previously treated.13 
Both of these studies, highlight the more rapid atherosclerosis seen in patients with DM, 
including mild angiographic lesions. 
Our results may also provide an explanation for the superior clinical outcomes of CABG 
compared to PCI in a DM population, as shown in the Future Revascularisation Evaluation 
in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) 
trial.14 Interestingly, the superior outcomes of CABG in this trial, unlike the Synergy between 
PCI with TAXUS and Cardiac Surgery (SYNTAX) trial were independent of the Syntax score, 
a finding that possibly reflects the better protection provided by grafting, not only for 
index lesions but also from atherosclerosis progression elsewhere in grafted coronary 
segments, which is not possible with PCI.14,15 Given that 41.6% of patients in the FFR(+)CR 
group underwent CABG, this may explain the lower rates of revascularisation which 
occurred in this group.
Another important finding of this study is the significant interaction for MACE observed 
between FFR groups and prior MI, suggesting that the higher MACE events were clustered 
mainly in DM patients with a prior MI carrying FFR(-)MT lesions, while patients without 
prior MI had much more benign outcomes and similar to the FFR(+)CR group. This finding 
supports the previous knowledge that incomplete revascularisation after ACS is strongly 
associated with major adverse cardiac events as shown in a sub-analysis from the Acute 
Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial, by Rosner et al.16 
Furthermore, a recently published study by Masrani et al, has shown that medically treated 
FFR negative lesions in ACS patients are associated with a significantly higher rate of 
adverse cardiac events as compared to medically treated FFR negative lesions in non-ACS 
patients, a finding which was also observed in patients with prior MI in our study, but 
similarly not seen in non-MI patients in our analysis.17 One possible explanation for the 
worse outcomes in DM with deferred revascularisation, including those patients with 
prior ACS, may center on the greater burden of vulnerable plaque and ongoing 
inflammation in these patients. Intravascular imaging studies have shown that DM 
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patients have a larger lipid index and higher prevalence of thin-cap fibroatheroma with 
macrophage infiltration, especially in patients with poorer gylcaemic control.18 Additionally, 
a recent sub-analysis of the PROSPECT study, has shown that patients with versus without 
DM presenting with ACS, have a higher non-culprit MACE, and when associated with a 
thin cap fibroatheroma there is a five-fold increased MACE rate at 3 years.19
Therefore, it seems reasonable that in patients with fast progressing atherosclerosis, such 
as patients with DM and/or ACS, combining FFR-ischaemia detection, which remains the 
cornerstone of our treatment strategy choice, with other intravascular imaging modalities, 
capable of identifying high risk plaque characteristics, may further refine our strategy and 
improve outcomes in these patients. In particular, two intravascular imaging modalities, 
optical coherence tomography (OCT) and near infrared spectroscopy (NIRS) may provide 
better accuracy than intravascular ultrasound IVUS for the detection of vulnerable 
plaque.20,21 Indeed, this hypothesis is being investigated in two ongoing large scale 
natural history studies; PROSPECT II and specifically in DM patients in the COMBINE 
registry.22,23 Finally, given the high rates of MACE observed in our study, DM patients 
undergoing deferred revascularisation should undergo stringent and intensive 
modification of risk factors, as intravascular imaging studies have suggested that the 
slowing of atheroma volume may be achieved as risk factors achieve treatment targets.24,25 
Our study has several potential limitations. Cox proportional hazards multiple regression 
models were used to correct for the baseline characteristics differences resulting from lack 
of randomisation, nonetheless these methods cannot control for unmeasured 
confounders. However, considering that the baseline characteristics were rather more 
favorable in the FFR(-)MT group, this further strengthens our findings. The duration of DM 
status is unknown for our patient population. Prior studies have shown that the duration 
of DM is associated with more abundant plaque burden and also more rapid disease 
progression, as such we cannot exclude the possibility that patients in the FFR(-)MT group 
may have had a longer duration of DM.26 However, considering that HbA1c was similar in 
both groups, as well as the significantly lower Syntax Score in the FFR(-)MT group, suggests 
that this possibility is unlikely. As was the case in the FAME II study, neither patients nor 
clinicians were blinded to the FFR result, therefore, in those patients with ongoing 
symptoms, knowledge of a prior borderline FFR measurement may have influenced the 
subsequent rates of TLR or rehospitalisation for ACS, however considering the retrospective 
nature of this study this was unavoidable.4 Medication compliance, was not captured in 
our database, representing another limitation of this analysis. Finally, patients included in 
our study, due to its nature, represent all-comer DM patients and therefore may be at 
higher risk than those DM patients which have been enrolled in prior randomized trials, 
and this may impact on the high MACE rate observed. Given that all DM patients 
undergoing an FFR guided revascularisation strategy during the study period were 
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included, we believe that rather than being a true limitation, this is representative of real 
world outcomes of an FFR-guided revascularisation strategy in such patients. 
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Abstract
Objective: To explore the predictors of deferred lesion failure (DLF) in patients with 
diabetes mellitus (DM) and lesions with a fractional flow reserve (FFR) >0.80 and to 
examine whether a predictive relationship between negative FFR values (>0.80-1.00) and 
DLF exists.
Background: DM is associated with rapidly progressive atherosclerosis and predictors of 
DLF in FFR negative lesions in this high-risk group are unknown.
Methods: All DM patients who underwent FFR-assessment between 1/01/2010 and 
31/12/2013 were included, and followed until 1/7/2015. Patients carrying ≥1 FFR negative 
lesion(s) were assessed for DLF, and multivariate models used to identify independent 
factors associated with DLF. 
Results: A total of 205 patients with 252 FFR >0.80 lesions were identified. At a mean 
follow-up of 3.1 ± 1.4 years, DLF occurred in 29/205 (14.1%) patients, 31/252 (12.3%) lesions. 
Using marginal Cox regression multivariate analysis, insulin requiring DM [HR 2.24 (95%CI; 
1.01-4.95), p=0.046] and prior revascularisation [HR 2.70 (95%CI 1.21-6.01), p=0.015] were 
identified as being associated with a higher incidence of DLF. Absolute FFR values in FFR 
negative lesions in DM patients are not predictive of DLF (receiver operating characteris-
tics (ROC) curve analysis: area under the curve (AUC): 0.57 ± 0.06, 95%CI 0.46-0.69). 
Conclusions: In DM patients with FFR negative lesions, insulin requiring DM and prior 
revascularisation are predictors for DLF. In contrast to non-DM patients, no predictive 
relationship between absolute negative FFR values (ranging >0.80-1.00) and the risk of 
DLF exists in DM patients.  
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Introduction
The global incidence and prevalence of Diabetes Mellitus (DM) is rapidly increasing, with 
the number of patients with DM expected to exceed 592 million worldwide by 2035(1). 
DM is an established independent risk factor for cardiovascular disease, associated with a 
poorer prognosis in both acute and stable coronary artery disease (CAD)(2,3). Additionally, 
DM is associated with more extensive atherosclerosis, a greater number of significant 
stenoses, longer lesions and more diffuse disease(4-6). As such, DM represents a high-risk 
condition, and diabetic patients with CAD have higher rates of death, non-fatal myocardial 
infarction (MI) and repeat revascularisation than non-diabetic patients(7). Whilst fractional 
flow reserve (FFR) has an extensive evidence base, a low proportion of patients with DM 
were included in the landmark studies(8-10). Recent evidence has suggested that deferred 
revascularisation based upon FFR in DM patients may not be associated with a similar low 
risk of MI or target lesion revascularisation as seen in non-DM patients(11-14). Whilst risk 
prediction models have been developed to better predict the risk of FFR-guided deferred 
lesion failure (DLF), such models may not be as applicable in DM patients, given the 
significantly different nature of atherosclerosis seen in this condition(15-17). This study 
sought to identify the factors associated with an increased risk of DLF and in particular to 
evaluate the predictive value of absolute FFR values in FFR negative lesions (ranging from 
0.81-1.00) in large real-world cohort of DM patients in which revascularisation was deferred 
based upon FFR. 
Methods
From a total of 3,379 patients who underwent FFR-guided revascularisation from January 
2010 until December 2013, we identified all DM patients. After excluding those patients 
who had complete FFR-guided revascularisation, 205 DM patients who had deferred re-
vascularisation of ≥1 lesion based upon a FFR >0.80 formed the final study population. All 
patients were followed until 1/7/2015. Baseline demographics were obtained utilising 
electronic medical records, as was data relating to the FFR measurement and baseline 
angiography.  Follow up events were obtained primarily from the electronic patient 
record and by telephone contact with primary care physicians or direct contact with 
patients where required. Follow up was complete in all patients.
FFR assessment was systematically performed in patients with intermediate native 
coronary lesions ranging from 40-80% diameter stenosis (DS), where no prior non-invasive 
test of ischaemia was performed or when these were inconclusive. FFR was not performed 
for culprit lesions in MI, lesions with TIMI flow <3, or when the operator deemed a lesion 
to be clearly of haemodynamic significance. Diabetes Mellitus was defined by patient 
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history and classified by treatment with diet, exercise, oral anti-diabetic medication or 
insulin. Visual assessment of reference vessel diameter, diameter stenosis, American Heart 
Association/American Cardiology College (AHA/ACC) lesion type and the presence of 
calcification and diffuse disease were noted for all lesions by two independent 
interventional cardiologists. Both reviewers were blinded to the clinical outcomes. A third 
interventional cardiologist was used in cases where discordance arose. In addition, the 
Syntax Score (SS) was calculated, based upon the index (time of FFR-measurement) 
coronary angiogram, by scoring all lesions >1.5mm with at least 50% diameter stenosis(18). 
For those patients with a prior coronary artery bypass graft (CABG), no SS was calculated. 
A FFR >0.80 was considered as non-significant and the patient underwent deferred revas-
cularisation. The primary outcome was deferred lesion failure (DLF), defined as any 
deferred lesion revascularisation (DLR) or deferred vessel myocardial infarction (DVMI). 
Owing to the retrospective nature of the study, and thus the inability to definitively 
attribute death to a deferred lesion, cardiac death was not included in the primary 
outcome. 
Statistical Methods: Patient and lesion level characteristics at the time of index FFR 
assessment were included in the univariate Cox proportional hazards multiple regression 
model and a marginal Cox model used to account for correlated data in patients having 
multiple deferred lesions. The model was reduced using a stepwise backward variable 
selection technique employing a threshold p>0.15 for removal. Variables entered in the 
model included: age (per year increment), male gender, index revascularisation, renal 
insufficiency, family history of CAD, FFR result, recent MI, multi-vessel CAD, current smoker, 
prior revascularisation, HbA1c and insulin requiring DM. Results are expressed as hazard 
ratio’s (HR) with 95% confidence intervals. Receiver-operating characteristics (ROC) curve 
analysis was used to evaluate the diagnostic performance of FFR in identifying DLF. ROC 
curves were generated and the area under the curve (AUC) calculated. AUC summarizes 
the diagnostic accuracy of a test; a perfect test is represented by an area of 1, whilst a poor 
test has an area of 0.5. A p value of <0.05 was considered significant. All analyses were 
conducted using SAS 9.3 (Cary, NC, USA). 
Results
Baseline patient and lesions characteristics: Baseline clinical, angiographic and lesion 
characteristics are noted in Table 1. The average age of patients was 69.7 ± 9.6 years, with 
42% insulin-requiring.  Patients had a high prevalence of cardiovascular risk factors; 46% 
had a history of myocardial infarction and 54% had prior revascularisation. The mean 
HbA1c level was 53.7 ± 10.5. In total there were 252 lesions which underwent deferred 
 revascularisation, with a mean FFR value 0.88 ± 0.05.  
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Table 1   Baseline clinical, angiographic and lesion characteristics in patients with  
and without DLF 
 
With DLF Without DLF
n=29 n=176
Age (years) (mean ± SD) 68.0 ± 8.8 70.0 ± 9.7
Men 18 (62%) 107 (61%)
Diabetes mellitus 29 (100%) 176 (100%)
    Insulin requiring DM 18 (62.1%) 69 (39.2%)
Left ventricle ejection fraction 53.1 ± 6.6 51.6 ± 10.6
Multi-vessel coronary artery disease 15 (51.7%) 100 (56.8%)
Family history of coronary artery disease 12 (41.4%) 49 (27.8%)
Hypertension 29 (100.0%) 168 (95.5%)
Hypercholesterolaemia 29 (100.0%) 169 (96.0%)
Current smoker 7 (24.1%) 34 (19.3%)
Renal insufficiency 4 (13.8%) 26 (14.8%)
HbA1c (mean ± SD) 58.0 ± 13.7 53.0 ± 9.7
Prior myocardial infarction 13 (44.8%) 80 (45.5%)
Remote myocardial infarction 6 (20.7%) 41 (23.3%)
Recent myocardial infarction 7 (24.1%) 39 (22.2%)
Prior percutaneous coronary intervention 16 (55.2%) 66 (37.5%)
Prior coronary artery bypass graft 7 (24.1%) 22 (12.5%)
Clinical syndrome at time of FFR performance:
Acute coronary syndrome 9 (31.0%) 64 (36.4%)
Non-acute coronary syndrome 20 (69.0%) 112 (63.6%)
Syntax Score (mean ± SD) 10.95 ± 5.51 10.95 ± 7.20
    Low scores (0-22) 21 (72.4%) 144 (81.8%)
    Intermediate scores (23-32) 1 (3.4%) 6 (3.4%)
    High scores (≥33) 0 (0.0%) 4 (2.3%)
    Unclassified, prior coronary artery bypass graft 7 (24.1%) 22 (12.5%)
FFR result (mean ± SD) 0.87± 0.05 0.88 ± 0.05
Lesion characteristics: lesion level
Number of lesions: 31 221
AHA/ACC lesion type classification:
    Type A 2 (6.5%) 31 (14.0%)
    Type B1 19 (61.3%) 117 (52.9%)
    Type B2 8 (25.8%) 58 (26.2%)
    Type C 2 (6.5%) 15 (6.8%)
Calcified lesion 5 (16.1%) 46 (20.8%)
Diffuse disease 8 (25.8%) 57 (25.8%)
Reference vessel diameter (mm)† 3.01 ± 0.34 2.92 ± 0.45
Diameter stenosis (%)† 59.68 ± 6.05 59.55 ± 8.41
Renal Insufficiency was defined as an estimated glomerular filtration rate, eGFR<60mL/min. †visual assesment
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Deferred lesion failure- Incidence and setting: During a mean follow-up of 3.1 ±1.4 
years, DLF occurred in 29/205 patients (14.2%) and 31/252 (12.3%) deferred lesions (Figure 1). 
Of the 31 lesions with DLF, DLR occurred in 30 lesions (11.9%) and 8 lesions (3.2%) resulted 
in subsequent DVMI. All DVMI were non-ST segment elevation MI (NSTEMI). In addition, 
14 lesions resulted in unstable angina pectoris and so the majority of lesions (22/31, 8.7% 
of all deferred lesions), resulted in subsequent acute coronary syndrome (ACS).  For those 
patients with stable or unstable angina, 52.2% (12/23) underwent repeat ischaemic detection 
prior to revascularisation, whilst clear angiographic progression was noted in the remainder 
(Table 1 appendix). 
Deferred lesion failure risk model: The univariate predictors for DLF are shown in Table 2. 
Following backward selection marginal Cox proportional modelling techniques, insulin- 
requiring DM [HR 2.24 (95%CI; 1.01-4.95), p=0.046] and prior revascularisation [HR 2.70 
(95%CI 1.21-6.01), p=0.015] were identified as independent predictors for DLF (Table 2). 
In addition, a trend for DLF with increasing HbA1c levels (per unit increase) was observed, 
HR 1.03 (95%CI; 1.00-1.07), although this fell short of statistical significance (p=0.066). 
Correlation between FFR value and the risk of DLF: Interestingly, ROC curve analysis, 
with an AUC 0.57 ± 0.06 (95%CI; 0.46-0.69), showed that absolute FFR values are an 
unreliable predictor for future DLF in DM patients with a negative FFR (Figure 2). 
Figure 1   Time-to-event estimates for deferred lesion failure (DLF) (lesion level analysis)
FFR denotes Fractional Flow Reserve; DLF denotes Deferred Lesion Failure.
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Figure 2   Receiver-operating curve (ROC) curve FFR value and risk of Deferred Lesion 
Failure (DLF)
FFR denotes Fractional Flow Reserve; AUC denotes Area Under the Curve; CI denotes Confidence 
Interval.
Table 2   Univariate and multivariate predictors of Deferred Lesion Failure (DLF) 
 
Univariate Analysis Multivariate Analysis
HR 95%CI p value HR 95%CI p value
FFR (per 0.05 decrease) 1.36 0.89-2.06 0.15
Male 1.07 0.50-2.30 0.86
Age (per year increase) 0.98 0.95-1.02 0.28
HbA1c 1.04 1.00-1.08 0.03 1.03 1.00-1.07 0.067
Insulin requiring DM 2.38 1.10-5.13 0.03 2.24 1.01-4.95 0.046
Renal Insufficiency 1.02 0.34-3.10 0.97
Recent MI 1.13 0.48-2.64 0.79
Family history CAD 1.81 0.84-3.89 0.13
Smoker 1.55 0.65-3.72 0.32
Multi-vessel CAD 0.68 0.32-1.43 0.31
Index revascularisation 0.74 0.25-2.19 0.60
Prior revascularisation 2.48 1.14-5.39 0.02 2.70 1.21-6.01 0.015
FFR denotes Fractional Flow Reserve; DM denotes Diabetes Mellitus; MI denotes Myocardial Infarction; CAD 
denotes Coronary Artery Disease
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Discussion
This study is the first to examine those clinical factors which are associated with a higher 
incidence of DLF in a population of only DM patients. As seen from the results, DLF in this 
high-risk group is common and more often results in subsequent ACS. The most important 
finding of this study is that in DM patients, insulin-requiring DM and prior revascularisation 
are associated with an increased risk of DLF. Interestingly in DM patients with a negative 
FFR, in contrast to what has been previously shown in non-DM patients, higher FFR values 
(closer to 1.0) are not associated with less risk than lower FFR values (closer to 0.80)(15).  
FFR is the guideline recommended reference standard invasive assessment of ischaemia 
in intermediate coronary lesions. Based upon the results of landmark trials, deferred revas-
cularisation in those lesions with a FFR >0.80 is associated with a low risk of future adverse 
cardiac outcomes(8-10). However, more recently, several studies have shown that deferred 
revascularisation based on FFR assessment of intermediate lesions in high risk patients 
and specifically in DM patients may not be as safe and is associated with worse outcomes 
than in non-DM patients(11,12). 
DM coronary disease is associated with a greater atherosclerosis burden and unique and 
unremitting progression(5). In the PRESTO trial, diabetic patients had a 33% increase over 
non-diabetic patients in new lesion formation over a nine month follow -up(19). Similarly, 
Figure 3   DLF rates per FFR quartiles >0.80-0.85, 0.86-90, 0.91-0.95, 0.96-1.00
DLF denotes Deferred Lesion Failure; FFR denotes Fractional Flow Reserve.
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in the DIABETES study, at 2-year follow-up, 50% of repeat revascularisations were as a 
result of progression in a vessel or segment remote from the one previously treated(20). 
Thus, whilst FFR is often seen as a binary assessment of ischaemia, the absence of FFR 
detected ischaemia in the setting of such rapid progression may not necessarily be 
reassuring. In the multivariate analysis in this study, insulin requiring DM and prior revascu-
larisation were identified as predictors of increased risk for DLF, both characteristics 
associated with increased burden, faster atherosclerosis progression and worse outcomes 
(21,22).
Furthermore, atherosclerotic disease in DM patients is associated with more vulnerable 
plaque, which may result in future clinical events irrespective of stenosis severity and 
progression in such lesions is often unpredictable. This may explain the differences in 
outcomes with deferred revascularisation and the lack of predictive effect of FFR values in 
DM patients as seen in our study, compared to previous reports(23). Indeed, Marso et al, 
have shown that significant differences in the composition of plaque exists in DM patients; 
with lesion length, plaque burden, necrotic core, and calcium content significantly greater 
in such patients(17). Additionally, the prevalence of thin cap fibroatheroma, a predictor of 
adverse outcomes, is more abundant in DM patients, especially amongst those patients 
with poorer gylcaemic control(24). Whether the trend observed in our study of a greater 
risk of DLF with increasing HbA1c levels, reflects such an increased prevalence of higher-risk 
atheroma is unknown. Finally, in the PROSPECT study, as in our study, insulin requiring DM 
was identified as an independent predictor (HR 3.32) of future non-culprit MACE, in lesions 
which were angiographically milder (diameter stenosis; median 36.2%) than even those 
non-ischaemic lesions included here(25). Together the findings from these studies extend 
to non-culprit/non-haemodynamically significant lesions in DM patients, the knowledge 
from multiple prior studies, that insulin treatment is associated with worse outcomes, 
either due to more aggressive disease or an adverse effect of insulin itself(22,26,27). 
Based upon several studies, it appears that there exists a linear relationship between FFR 
values and the risk of major adverse cardiac events, with lesions which are close to FFR 1.0 
being associated with a lesser risk than those lesions closer to 0.80(15,16,23,28). However, 
Liu et al have recently examined this relationship in a group of diabetic and non-diabetic 
patients with stable angina pectoris(12). This study confirmed that amongst non-diabetic 
patients, higher FFR values are associated with a lower risk of major adverse cardiac events 
(MACE), defined as a composite of all cause death, non-fatal MI and any revascularisation. 
However, in DM patients the risk of MACE was independent of the FFR value. Our study, in 
which we studied a more lesion specific outcome (DLF), confirms this lack of predictive 
effect of FFR values (range 0.81-1.00) in DM patients.  
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Whether this lack of predictive effect of FFR values is due to a higher prevalence of 
microvascular dysfunction in DM patients is a possibility. Recently Lee et al, have shown 
that in patients with FFR values >0.80 that an elevated index of microvascular resistance 
and a low coronary flow reserve is associated with the worst clinical outcomes(13). 
Furthermore, within this group, DM was identified as an independent predictor of poor 
outcomes. These findings are in keeping with those previously mentioned studies 
showing that deferred revascularisation based upon FFR is not as safe in DM patients as 
compared to non-DM patients(11). In the present study, based upon the ROC curve 
analysis, we show that further efforts to define an alternative cut-off value to improve 
outcomes with a FFR guided-revascularisation strategy in DM patients appears to be of 
little value. Whether the addition of prospective microvascular assessments may improve 
outcomes in DM patients with FFR negative lesions remains to be answered. 
Study Limitations
The present study is a single-center, non-randomized, observational study and thus the 
results should be considered as hypothesis generating. Cox proportional hazards multiple 
regression models were limited by the sample size and number of events to 3 factors to 
avoid over-fit models. Prior studies have shown that the duration of DM is associated with 
more abundant plaque burden and more rapid disease progression, as such we cannot 
exclude the possibility that patients with subsequent DLF may have had a longer duration 
of DM. Additionally, although insulin status was known for all patients, whether patients 
had type 1 versus type 2 DM was unknown. Nonetheless, our study confirms the findings 
of multiple other studies, which have indicated those DM patients treated with insulin 
have significantly worse outcomes than DM patients who are not insulin requiring. 
Whether the poorer outcomes in those patients treated with insulin reflects more advanced 
vascular disease in these patients, a longer duration of DM or an effect of insulin itself, 
cannot be answered from this study. As was the case in the FAME II study, neither patients 
nor clinicians were blinded to the FFR result, therefore, in those patients with ongoing 
symptoms, knowledge of a prior borderline FFR measurement may have influenced the 
subsequent rates of TLR or rehospitalisation for ACS, however considering the retrospective 
nature of this study this was unavoidable, nevertheless such a bias was not reflected in the 
ROC analysis(29). In addition, the majority of subsequent revascularisations were driven by 
ACS or repeat ischaemic evaluation and as such we believe our practice is a close to 
guideline recommended practice as is achievable in a real-world setting (Table 1 
appendix).
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Conclusion
Lesion failure in FFR guided deferred revascularisation in DM patients is considerable and 
is unpredictable based upon FFR absolute values and efforts to define a more accurate 
FFR cut-off appear futile. Clinical characteristics such as IDDM and prior revascularisation 
provide greater predictive accuracy for DLF. These findings should be considered in DM 
patients undergoing deferred revascularisation based upon FFR assessment for better risk 
stratification.  
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Appendix table 1   Deferred Lesion Failure during follow 
 
Patient DM Initial Vessel
Assessed
DVMI DLR Diagnosis DLR Reason
1 Yes LAD & D No Yes SAP Disease progression LAD & D
2 Yes LAD No Yes UAP Repeat FFR LAD 0.72
3 Yes LAD No Yes SAP Disease progression
4 Yes Cx Yes Yes NSTEMI Repeat FFR Cx 0.77
5 Yes LAD Yes Yes NSTEMI Disease progression
6 Yes Cx & AL No Yes UAP Disease progression Cx & AL
7 Yes RCA No Yes SAP FFR RCA 0.79
8 Yes RCA No Yes SAP Disease progression
9 Yes RCA No Yes UAP Disease progression
10 Yes Cx Yes Yes NSTEMI Cx culprit. Disease progression
11 Yes Cx No Yes UAP Repeat FFR Cx 0.78
12 Yes RCA No Yes UAP Repeat FFR RCA 0.77.
13 Yes LAD Yes Yes NSTEMI LAD culprit. Disease progression
14 Yes RCA No Yes SAP Positive SPECT. RCA CTO
15 Yes LAD No Yes UAP Repeat FFR LAD 0.71
16 Yes RCA Yes Yes NSTEMI RCA culprit. Disease progression
17 Yes RCA Yes No NSTMEI Revascularisation not successful
18 Yes LAD No Yes UAP Repeat FFR LAD 0.71
19 Yes AL No Yes UAP Repeat FFR complicated by dissection
20 Yes LAD No Yes UAP Disease progression
21 Yes LAD No Yes UAP Disease progression
22 Yes RCX No Yes UAP Disease progression
23 Yes AL No Yes UAP Disease progression
24 Yes Cx No Yes SAP Repeat FFR Cx 0.77 
25 Yes RCA No Yes SAP Positive SPECT
26 Yes LAD Yes Yes NSTEMI LAD culprit.  Disease progression  
27 Yes LAD Yes Yes NSTEMI LAD culprit.  Disease progression
28 Yes Cx No Yes SAP Positive SPECT. Disease progression
29 Yes RCA No Yes UAP Disease progression
DM denotes Diabetes Mellitus; TVMI denotes target vessel myocardial infarction; TLR denotes target lesion 
revascularisation; LAD denotes left anterior descending artery; Cx denotes circumflex artery; OM denotes 
obtuse marginal artery; AL denotes Anterolateral artery; UAP denotes unstable angina pectoris; SAP denotes 
stable angina pectoris; STEMI denotes ST elevation myocardial infarction; NSTEMI denotes non-ST elevation 
myocardial infarction; FFR denotes fractional flow reserve; SPECT denotes single-photon emission computed 
tomography.
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Abstract
Objectives: We sought to investigate the relationship between thin-cap fibroatheromas 
(TCFAs) on major adverse cardiac events (MACEs) arising from medically treated non-culprit 
lesions (NCLs) in patients with acute coronary syndromes (ACS) with and without diabetes 
mellitus (DM). 
Background: MACEs occur frequently in patients with DM and ACS. The impact of plaque 
composition on subsequent MACEs in DM patients with ACS is unknown. 
Methods: In the PROSPECT (Providing Regional Observations Study Predictors of Events in 
the Coronary Tree) study, using 3-vessel radiofrequency intravascular ultrasound, we analysed 
the incidence of NCL-MACE in 2 propensity-matched groups according to the presence of 
DM and TCFA.
Results: Among 697 patients, 119 (17.7%) had DM. The 3-year total MACE rate (29.4% vs. 
18.8%; p=0.01) was significantly higher in patients with versus without DM, driven by a 
higher rate of NCL-MACE in DM (18.7% vs. 10.4%; p=0.02). Propensity score matching 
generated 2 balanced groups with and without DM of 82 patients each. Among DM 
patients, the presence of ≥1 TCFA was associated with higher NCL-MACE at 3 years (27.8% 
vs. 8.9% in patients without a TCFA, hazard ratio: 3.56; 95% confidence interval: 0.98 to 
12.96; p=0.04). DM patients without a TCFA had a similar 3-year rate of NCL-MACE as 
patients without DM (8.9% vs. 8.9%; hazard ratio: 1.09; 95% confidence interval: 0.27 to 4.41; 
p=0.90).
Conclusions: ACS patients with DM and ≥1 TCFA have a high rate of NCL-MACE at 3 years. 
In contrast, the prognosis of ACS patients with DM but no TCFAs is favorable and similar to 
patients without DM. 
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Introduction
Patients with diabetes mellitus (DM) and those presenting with acute coronary syndromes 
(ACS) are known to have a higher risk of adverse events after percutaneous coronary 
intervention (PCI)(1-5). It is believed that these unfavorable outcomes are due not only 
to worse outcomes from the PCI-treated segments (culprit lesions), but also due to 
progression of disease elsewhere in the coronary tree, (i.e. from non-culprit lesions [NCL]), 
which are often not apparent on baseline angiography(6). Whether intravascular ultra- 
sound (IVUS) assessment can identify morphologic characteristics of untreated NCLs 
which predict future events was examined in the Providing Regional Observations Study 
Predictors of Events in the Coronary Tree (PROSPECT) study(7). PROSPECT demonstrated 
that lesions that are otherwise mild on angiographic evaluation but have features consistent 
with vulnerable plaques, including thin cap fibroatheroma (TCFA), plaque burden (PB) 
≥70%, and a minimal lumen area (MLA) of ≤4 mm2 are prone to rapid lesion progression 
and major adverse cardiac events (MACE). Furthermore, insulin-treated DM was found 
to be a positive predictor for future MACE arising from untreated NCLs (NCL-MACE). 
Marso et al(5), in a descriptive overview of the gray-scale and radiofrequency IVUS findings 
in DM patients from the PROSPECT trial, reported that patients with DM had higher rates 
of NCL-MACE at 3 years than those without DM or with metabolic syndrome, a finding 
confirmed by others(8). They also showed that patients with as opposed to without DM 
were more likely to have ≥1 NCL containing ≥2 high-risk plaque features shown to correlate 
with future unanticipated MACE.
Despite these findings, the importance of TCFAS in explaining the high-risk nature of DM 
has been incompletely characterised. We therefore performed a further analysis from 
PROSPECT to isolate the effect of TCFAs in combination with DM on future NCL-MACE.
Methods
The design of the PROSPECT study has been previously described(7). PROSPECT enrolled 
697 ACS patients after successful and uncomplicated PCI of all angiographically evident 
culprit coronary lesions. Following PCI, both gray-scale and radiofrequency intravascular 
ultrasonography of the left main coronary artery and the proximal 6 to 8 cm of each of 
the 3 major epicardial coronary arteries was performed. Angiographic core laboratory 
qualitative and quantitative measurements were obtained for each 1.5 mm of the coronary 
tree, including each epicardial vessel and side branch that was ≥1.5 mm in diameter. 
Analysis of all angiographic lesions with ≥30% visible diameter stenosis was also 
pre-specified. In the IVUS core laboratory, a lesion was defined as at least 3 consecutive 
frames with a PB of ≥40%. Plaque components were identified by radiofrequency analysis 
as dense calcium, necrotic core, fibro-fatty tissue, or fibrous tissue, with the cross-sectional 
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area and percentage of total plaque area reported for each component. Such lesions were 
further classified as either thin-cap fibroatheromas, thick-cap fibroatheromas, pathologic 
intimal thickening, fibrotic plaques, or fibrocalcific plaques(7). A fibroatheroma was defined 
as the presence of >10% confluent necrotic core. If ≥30° of necrotic core abutted the lumen 
in ≥3 consecutive frames, the fibroatheroma was classified as a TCFA; otherwise, it was 
categorised as a thick-cap fibroatheroma.
Endpoints and definitions: DM was defined according to medical treatment, and 
whether treated with or without insulin. The definitions of the endpoints assessed and the 
and event adjudication process for has been previously described(7). The primary endpoints 
were adjudicated by a clinical events committee, using original source documents. 
The pre-specified primary endpoint in PROSPECT was the incidence of MACE (a composite 
of death from cardiac causes, cardiac arrest, myocardial infarction, or rehospitalisation due 
to unstable or progressive angina). On the basis of follow-up angiography, MACE were 
further adjudicated as occurring at initially treated sites (culprit lesions) or at previously 
untreated coronary segments (NCLs). If follow-up angiography was not performed, 
the site associated with the event was classified as indeterminate. 
Statistical methods: NCL-MACE were evaluated according to the presence of medically- 
treated DM. To isolate the effects of DM, two equal-sized propensity matched groups 
were created based on the following variables: gender, hypertension, hyperlipidaemia, 
family history of coronary disease, current smoking, presence of ≥1 lesion with PB >70%, 
presence of ≥1 lesion with MLA <4 mm2, and presence of ≥1 TCFA. Matching was 
performed using the SAS macro %GREEDMTCH (SAS Institute, Cary, North Carolina) (8), 
which implements a Greedy 5 1 Digit Match algorithm that matches pairs using their 
propensity score that is iteratively rounded to 1 less decimal place if no perfect match is 
found. In the matched cohort used in this analysis, 61.0% of the pairs have propensity 
scores that are perfect matches to the fifth decimal place, and the largest difference in the 
propensity scores of matched pairs was 0.04914; the c-statistic for the propensity score 
model was 0.697. 
To evaluate the impact of DM and TCFA on future adverse events originating from NCLs, 
the NCL-MACE rate was evaluated according to presence of DM and TCFA in the matched 
populations. 
Categorical outcomes were compared by the χ2 test. Continuous variables are presented 
as mean ± SD and were compared by the t-test. Cumulative event rates were estimated 
using time-to-event methods, and were compared by the log-rank test. A P value of <0.05 
was considered statistically significant. All analyses were performed with SAS version 9.2 
(SAS Institute).
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Results
Baseline characteristics: Of the 697 patients enrolled in PROSPECT, 119 (17.1%) had 
medically- treated DM. Propensity matching generated two groups with and without DM, 
each with 82 patients. The baseline characteristics of the matched DM and non-DM 
groups are shown in Table 1, and the baseline characteristics of the unmatched groups 
appear in the appendix, Table 1. Before matching, patients with compared to those without 
DM were older, and had a higher incidence of hypertension and hypercholesterolaemia, 
but a lower incidence of smoking. The baseline characteristics were well balanced after 
matching. 
Table 1   Baseline clinical characteristics and medication compliance in the propensity 
matched groups with and without diabetes 
 
  Diabetes 
 Mellitus
No Diabetes 
Mellitus
p-value
n=82 n=82
Age, years, mean ± SD 61.9 ± 11.3 60.9 ± 11.0 0.63
Male, n (%) 76.8% (63) 78.0% (64) 0.85
Diabetes mellitus, n (%) 100.0% (82) 0.0% (0) <0.0001
    Insulin-treated, n (%) 12.2% (10) 0.0% (0) 0.001
Prior MI, n (%) 8.5% (7) 9.9% (8) 0.77
History of known CAD (stenosis ≥50%), n (%) 13.4% (11) 13.8% (11) 0.95
Family history of CAD, n (%) 34.1% (28) 32.9% (27) 0.87
Hypertension, n (%) 57.3% (47) 54.9% (45) 0.75
Hypercholesterolaemia, n (%) 57.3% (47) 57.3% (47) 1
Smoking, n (%) 42.7% (35) 39.0% (32) 0.63
Clinical syndrome at presentation:
    ST-segment elevation MI >24 hours, n (%) 31.7% (26) 25.6% (21) 0.39
    Non-ST-segment elevation MI, n (%) 67.1% (55) 72.0% (59) 0.5
    Unstable angina, n (%) 1.2% (1) 2.4% (2) 1
Creatinine clearance (mL/min)* 97.1 [71.1, 127.8] 88.9 [71.5, 114.8] 0.1
HbA1c* 6.70 [6.20, 7.70] 5.60 [5.10, 5.85] <0.0001
Cardiac Medications
Any lipid lowering medication:
       At discharge, n (%) 89.0% (73) 90.2% (74/82) 0.8
       At 3 years, n (%) 92.3% (60) 90.7% (68/75) 0.73
Statins:
       At discharge, n (%) 84.1% (69) 89.0% (73/82) 0.36
       At 3 years, n (%) 86.2% (56) 89.3% (67/75) 0.57
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The IVUS characteristics of patients with and without DM for the matched and unmatched 
cohorts are shown in Table 2 and the appendix, Table 2, respectively. In the unmatched 
analysis patients with as compared to those without DM showed a trend towards a higher 
incidence of NCLs with PB ≥70% and/or MLA ≤4 mm2, and had a significantly higher 
incidence of lesions with all 3 high risk characteristics (TCFA, PB ≥70% and MLA ≤4 mm2). 
After matching, these variables were similarly distributed. The angiographic and IVUS 
characteristics of the individual lesions were not significantly different in both the matched 
and unmatched groups (Table 3 and appendix, Table 3 respectively). Of note, the average 
diameter stenosis (DS) of the NCLs in patients with and without DM in the matched 
groups by quantitative coronary angiography (QCA) was mild (36.2% vs. 37.9% for angio-
Table 1   Continued 
 
  Diabetes 
 Mellitus
No Diabetes 
Mellitus
p-value
n=82 n=82
Lipid lowering medication (non statin):
       At discharge, n (%) 11.0% (9) 3.7% (3/82) 0.07
       At 3 years, n (%) 12.3% (8) 6.7% (5/75) 0.25
Aspirin:
       At discharge, n (%) 97.6% (80) 96.3% (79/82) 1
       At 3 years, n (%) 92.3% (60) 84.0% (63/75) 0.13
Thienopyridines:
       At discharge, n (%) 98.8% (81) 97.6% (80/82) 1
       At 3 years, n (%) 47.7% (31) 33.3% (25/75) 0.08
ACE inhibitors:
       At discharge, n (%) 69.1% (56) 69.5% (57/82) 0.96
       At 3 years, n (%) 63.1% (41) 61.3% (46/75) 0.83
Angiotensin receptor blocker:
       At discharge, n (%) 15.9% (13) 5.0% (4/80) 0.02
       At 3 years, n (%) 23.1% (15) 12.2% (9/74) 0.09
Beta blockers:
       At discharge, n (%) 91.5% (75) 91.5% (75/82) 1
       At 3 years, n (%) 80.0% (52) 88.0% (66/75) 0.19
Calcium channel blockers:
      At discharge, n (%) 20.0% (16) 8.6% (7/81) 0.04
      At 3 years, n (%) 20.6% (13) 14.7% (11/75) 0.36
*Median and interquartile range; CAD denotes coronary artery disease; MI denotes myocardial infarction; PCI 
denotes percutaneous coronary intervention; CABG denotes coronary artery bypass graft surgery.
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5graphically evident lesions and 13.2% vs. 12.6% for IVUS detected lesions, respectively). 
The baseline, demographic, and IVUS findings of DM as well as non- DM patients according 
to presence versus absence of TCFA are presented in appendix Tables 5 and 6, respectively. 
Clinical Outcomes: Three-year clinical outcomes in patients with and without DM in the 
matched and unmatched groups are presented in Table 4 and in the appendix, Table 4, 
respectively. In the unmatched analysis, the total 3-year MACE rate was significantly higher 
in patients with vs. without DM (29.4% vs. 18.8%, HR: 1.66; 95%CI: [1.11, 2.49], p=0.01). The 
same was also true for NCL-MACE (18.7% vs. 10.4%; HR: 1.84; 95%CI: [1.09, 3.10], p=0.02). 
After propensity matching, DM was associated with higher total MACE (32.5% vs. 15.2%, 
HR: 2.35; 95%CI: [1.17, 4.72], p=0.01), and a trend towards higher NCL-MACE (18.7% vs. 8.9%, 
HR 2.22 [0.88, 5.56], P=0.08). The greater NCL-MACE rate in patients with DM was driven 
mainly by rehospitalisation for unstable or progressive angina, and almost all hospitalised 
patients required revascularisation. Comparing patients with and without DM, the greater 
MACE rate in patients with DM was driven by NCL-related events; there were no significant 
differences in MACE arising from culprit lesions in both the unmatched and matched 
comparisons (Figure 1, Table 4 and appendix Table 4).
Table 2   Patient-level non-culprit lesion  baseline IVUS findings in the propensity 
matched groups with and without diabetes 
 
  Diabetes No Diabetes p-value
n=82 n=82
Number of IVUS non-culprit lesions* 5 [4, 6] 5 [4, 7] 0.1
IVUS non-culprit lesions - volumetric data
Total lesion length (mm)* 67.85 [47.53, 97.98] 82.38 [46.11, 107.18] 0.25
Plaque volume (%) * 49.3 [46.7, 51.9] 49.3 [46.6, 52.6] 0.94
Prevalence of patients with ≥1 high-risk non-culprit lesion characteristic 
MLA ≤4 mm2, % (n) 57.3% (47) 57.3% (47) 1
PB ≥70%, % (n) 39.0% (32) 40.2% (33) 0.87
TCFA, % (n) 52.4% (43) 51.2% (42) 0.88
MLA ≤4 mm2 and PB ≥70%, % (n) 29.3% (24) 31.7% (26) 0.73
MLA ≤4 mm2 and TCFA, % (n) 34.1% (28) 31.7% (26) 0.74
PB ≥70% and TCFA, % (n) 25.6% (21) 24.4% (20) 0.86
All three high-risk characteristics, % (n) 20.7% (17/82) 20.7% (17/82) 1
*Median and interquartile range; IVUS denotes intravascular ultrasound; MLA denotes minimum lumen area; 
PB denotes plaque burden; TCFA denotes thin cap fibroatheroma.
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As shown in Figure 2, among matched group patients with DM, the presence of ≥1 TCFA 
was strongly associated with a higher rate of NCL-MACE at 3 years, compared to patients 
without a TCFA (27.8% vs. 8.9% HR: 3.56, 95%CI: [0.98,12.96], p=0.04). A similar trend was 
also observed in patients without DM, but the difference was not significant (Figure 2). 
Table 3   Quantitative coronary angiography of the non-culprit lesions in the 
propensity matched groups with and without diabetes 
 
  Diabetes No Diabetes p-value
Angiographic defined lesions  n=193 n=208 
Reference vessel diameter (mm)* 2.36 [1.86, 2.93] 2.19 [1.88, 2.72] 0.09
Minimal lumen diameter (mm)* 1.53 [1.14, 1.97] 1.35 [1.11, 1.73] 0.02
Diameter stenosis (%)* 36.2 [31.1, 44.2] 37.9 [33.1, 46.8] 0.09
Lesions with QCA DS ≥50% 17.6% (32/182) 18.8% (37/197) 0.76
Lesions with QCA DS ≥70% 4.4% (8/182) 4.1% (8/197) 0.87
Thrombus 0.5% (1/193) 0.5% (1/208) 1
Eccentricity 6.2% (12/193) 3.4% (7/208) 0.18
Coronary artery lesion location
Left main 1.6% (3) 0.0% (0) 0.11
Left anterior descending (or branches) 37.5% (72) 38.6% (80) 0.81
Left circumflex (or branches) 31.3% (60) 29.0% (60) 0.62
Right (or branches) 29.7% (57) 32.4% (67) 0.56
IVUS defined lesions n=397 n=429
Reference vessel diameter (mm)* 2.94 [2.55, 3.44] 2.99 [2.53, 3.44] 0.71
Minimal lumen diameter (mm)* 2.47 [2.03, 2.97] 2.49 [2.07, 3.10] 0.61
Diameter stenosis (%)* 13.2 [6.9, 23.0] 12.6 [6.5, 22.5] 0.55
Lesions with QCA DS ≥ 50% 2.0% (8) 1.9% (8) 0.88
Lesions with QCA DS ≥ 70% 0.3% (1) 0.0% (0) 0.48
Thrombus 0.3% (1) 0.2% (1) 1
Eccentricity 1.0% (4) 1.9% (8) 0.3
Coronary artery lesion location
Left main 5.0% (20) 4.2% (18) 0.56
Left anterior descending (or branches) 31.0% (123) 32.6% (140) 0.61
Left circumflex (or branches) 25.4% (101) 25.2% (108) 0.93
Right (or branches) 38.5% (153) 38.0% (163/429) 0.87
*Median and interquartile range; QCA denotes quantitative coronary angiography; DS denotes diameter 
stenosis; IVUS denotes intravascular ultrasound.
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DM patients without a TCFA had a similar 3-year rate of NCL-MACE as all patients without 
DM (8.9% vs. 8.9%, HR: 1.09, 95%CI: [0.27,4.41], p=0.90). There was also no significant 
difference in the 3-year NCL-MACE rate in DM and non-DM patients without a TCFA (8.9% 
vs. 5.2% respectively, HR: 1.69, 95%CI: [0.28,10.10], p=0.57). Conversely, in patients with a 
TCFA, the 3-year NCL-MACE rate was higher in DM compared to non-DM patients (27.8% 
vs. 12.3% respectively, HR: 2.54, 95%CI: [0.87, 7;45], p=0.08). Finally, 7 patients with DM who 
developed NCL-MACE during follow-up had 1 or more TCFAs identified in their coronary 
tree at baseline by intravascular imaging. Of these, 3 plaques responsible for the NCL-MACE 
were originally TCFAs, 2 were thick-cap fibroatheromas, and 2 were pathologic intimal 
thickening. A TCFA was present in 3 of 4 coronary arteries in which the NCL-MACE arose 
from a non-TCFA. Among 5 non-DM patients with at least 1 baseline TCFA and subsequent 
NC-MACE, 4 events arose from a TCFA. 
Figure 1   Time-to-event estimates of culprit lesion related MACE, non-culprit lesion 
related MACE, indeterminate MACE, and any MACE according to the presence 
of diabetes at 3 years in the propensity matched groups of patients with and 
without diabetes
HR denotes hazard ratio. CI denotes confidence interval. NCL denotes non-culprit lesion. MACE 
denotes major adverse cardiac events.
Th
re
e-
Y
ea
r M
A
C
E
 %
45
40
35
30
25
20
15
10
5
0
32.5
15.2 14.3
11.4
18.7
8.9
5.7
1.3
Any MACE Culprit Lesion
MACE
Non Culprit
Lesion MACE
Indeterminate
MACE
HR:4.56
(95%CI:0.51, 40.8)
p = 0.14
HR:2.22
(95%CI:0.88, 5.56)
p = 0.08
HR:1.25
(95%CI:0.51, 3.07)
p = 0.63
HR:2.35
(95%CI:1.17, 4.72)
p = 0.01
Diabetes Mellitus
No Diabetes Mellitus
78
Chapter 5
Discussion
In the present analysis from the PROSPECT study, the increased risk of long-term MACE in 
patients with DM compared to those without DM was due to a greater rate of unanticipated 
events arising from untreated NCLs. Moreover, this risk was predominately isolated to 
those patients with DM and a TCFA. A synergistic relationship was present between 
diabetic status and lesion phenotype such that patients with DM and a TCFA had a greater 
risk of 3-year NCL-MACE than patients without DM and a TCFA. Conversely, patients with 
DM but without a TCFA had a similar prognosis as patients without DM (with or without 
a TCFA). 
Figure 2   Time-to-event estimates of non-culprit lesion-related MACE, according to  
the presence of diabetes and/or a TCFA at 3 years in the propensity matched 
groups of patients with and without diabetes
DM denotes diabetes mellitus. TCFA denotes thin-cap fibroatheroma. HR denotes hazard ratio.  
CI denotes confidence interval. NCL denotes non-culprit lesion. MACE denotes major adverse 
cardiac events.
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Our study extends the prior analysis of Marso et al (5) by focusing on the role of the TCFA 
in patients with and without DM. TCFAs are more prevalent in patients with DM and may 
reflect the greater level of inflammation and macrophage infiltration predisposing to 
future ACS in these patients (9–11).  In the present study in which propensity matching 
was used to eliminate the effects of measured confounders, DM patients had a 32.5% 
3-year MACE rate, with more than half of events arising from angiographically mild NCLs. 
Furthermore, the presence of at least one TCFA in patients with DM was associated with a 
>3-fold higher MACE rate as compared to DM patients without a TCFA, and >5-fold higher 
as compared to patients without DM or TCFA, thus representing a very high-risk group for 
future adverse events.
In the overall PROSPECT population, DM patients had a significantly higher rate of 
NCL-MACE than non-DM patients. A similar trend was present in the propensity-matched 
analysis, which did not reach statistical significance, likely because of reduced power. In 
conjunction with the findings of Marso et al. (5), the current analysis demonstrates that the 
worse outcomes in patients with versus without DM can be ascribed not only to a higher 
prevalence of high-risk lesions at baseline, but also to more rapid progression of athero-
sclerosis at NCL sites, particularly TCFAs. 
No prior study has specifically examined the impact of TCFA and DM in ACS patients. 
However, Nasu et al. (12) reported that the atherosclerotic lesions of DM patients have an 
increased amount of dense calcium and necrotic core as well as a greater frequency of 
TCFA and fibrocalcific lesions. Nicholls et al. (13) reported that DM is associated with more 
extensive atherosclerosis, inadequate compensatory remodelling, and accelerated plaque 
progression. The present study extends the findings from these 2 prior analyses. 
Our results also suggest a mechanistic explanation for the greater rates of MACE after PCI 
in patients with DM (3,14) and explain why coronary artery bypass graft surgery (CABG) 
may be superior to PCI in diabetic patients with extensive coronary artery disease (15,16). 
As shown in our analysis, the main driver of 3-year MACE in DM patients was not events 
originating from the treated culprit lesions (e.g., from restenosis or stent thrombosis), but 
rather from new lesions arising from medically treated NCLs. Fewer than 2% of these NCLs 
had an angiographic diameter stenosis of >50%, and thus would not be treated by PCI. 
Indeed, such lesions are not even registered in anatomic risk instruments such as the 
Syntax score. Anatomic risk scores may thus be of less utility in patients with DM than 
those without DM. Furthermore, because almost all NCLs were angiographically mild at 
baseline, and few had a MLA <2.5 mm2 (7), it is unlikely that many of these lesions would 
be ischaemic at baseline (17,18). Thus, targeting only ischaemic lesions (e.g., using the 
recently proposed functional Syntax score approach) (19) would be unlikely to meaningfully 
improve PCI outcomes in DM patients. Moreover, the high event rates observed in DM 
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patients in our study occurred despite tight monitoring and high adherence with 
guideline directed medical therapies, far beyond that typically achieved in current daily 
practice (20). 
Thus, because they ignore vulnerable plaque, the current risk models are suboptimal to 
accurately predict future adverse events in high-risk populations, such as those with DM. 
Further studies are required to determine whether a combination of intravascular imaging 
plus functional assessment of coronary lesions might provide better risk stratification in 
diabetic patients, and as described in the following section, improve choice of therapy. 
Furthermore, newer intravascular imaging modalities including near infrared spectroscopy 
and optical coherence tomography may provide advantages over IVUS for the detection 
of vulnerable plaques (21,22). Natural history studies such as PROSPECT are required to 
validate the utility of these imaging tools. 
The present study also has potential implications for the therapeutic approach to patients 
with DM. In the setting of complex multi-vessel disease, CABG is an excellent option 
because it bypasses many untreated vulnerable NCLs in the same territories as the 
ischaemic culprit lesions. CABG is not an optimal solution, however, for vessels with only 
non-ischaemic but otherwise high-risk NCLs, because of the high risk of graft occlusion 
from competitive flow (23). In the PRAMI (Preventive Angioplasty in Myocardial Infarction) 
trial (24), PCI of all angiographically detected NCLs with diameter stenosis >50% in patients 
presenting with ST-segment elevation MI and multi-vessel disease resulted in better 
outcomes than treatment of the infarct lesion only, suggesting that a combination of 
ischaemia relief and “preventive” plaque passivation might be beneficial in high-risk ACS 
patients. However, the underlying severity (and ischaemic potential) of these lesions has 
not been described, and composition of these plaques is unknown. Finally, proprotein 
convertase subtilisin/kexin type 9 inhibitors have shown great promise in markedly 
reducing low-density lipoprotein levels beyond that achieved by high-dose statins (25,26), 
and also warrant study in high-risk DM patients with ACS and vulnerable plaque. 
STUDY LIMITATIONS. The current report is on the basis of a post hoc patient-level analysis 
and should therefore be considered hypothesis generating. The sizes of the matched 
groups were modest, although the results were consistent with those from the entire 
study population. Nonetheless, propensity matching cannot control for unmeasured 
confounders. Although the rate of guideline directed medication use was high throughout 
the study duration, we cannot be certain that risk factor control was similar in both groups. 
Moreover, the medication adherence in this study is superior to that achieved in daily 
clinical practice and therefore the present outcomes should be considered as the best 
achievable with medical therapy. Follow-up angiography was not available in all patients 
with events; therefore, the origin of these events was classified as indeterminate. This may 
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have led to an underestimation of either the culprit lesion or NCL event rates. We have 
thus presented the total MACE rates as well as the NCL-MACE rates in patients with and 
without DM to place these results in perspective. The present study cannot be used to 
establish causality given the limited numbers of events, the occurrence of some events at 
lesion sites without baseline intravascular imaging, and the absence of serial follow-up 
imaging and angiography in all patients. Finally, because of the limited resolution of IVUS, 
it is possible that not all fibroatheromas defined as TCFAs had a cap thickness of <65 mm, 
the usual pathologic criterion. Furthermore, because fractional flow reserve was not 
routinely performed in PROSPECT, we cannot exclude that some NCLs may result in 
ischaemia, although the proportion is likely to be small given the mild diameter stenosis 
of these lesions (27). 
Conclusions
These limitations notwithstanding, the present study demonstrates that in high-risk 
patients presenting with ACS and DM, the presence of an untreated TCFA is associated 
with a very high rate of MACE at 3 years, explaining to a large extent the poor prognosis of 
the high-risk diabetic cohort. Conversely, the prognosis of DM patients without TCFA was 
similar to that of the patient without DM. Considering the increasing global prevalence of 
DM, further studies are warranted to determine whether identification of vulnerable 
plaques by either intravascular or noninvasive imaging in high-risk DM patients might 
inform more accurate prognosis and improved decision making regarding potent medical 
therapies and strategies for revascularisation.
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Supplemental Appendix
Table 1   Baseline clinical characteristics and medication compliance in the entire 
study population with and without diabetes 
 
  Diabetes No Diabetes p-value
n=119 n=575
Age, years, mean ± SD 62.1 ± 11.8 58.1 ± 11.2
Male, n (%) 71.4% (85) 77.2% (444) 0.18
Diabetes mellitus, n (%) 100.0% (119) 0.0% (0) <0.0001
    Insulin-treated, n (%) 17.6% (21) 0.0% (0) <0.0001
Prior MI, n (%) 10.9% (13) 10.5% (60/571) 0.89
History of known CAD (stenosis ≥50%), n (%) 16.0% (19) 13.3% (75/563) 0.45
Family history of CAD, n (%) 32.7% (32/98) 47.0% (242/515) 0.009
Hypertension, n (%) 63.2% (74/117) 42.9% (245/571) <0.0001
Hypercholesterolaemia, n (%) 60.2% (68/113) 40.8% (211/517) 0.0002
Smoking, n (%) 39.3% (46/117) 49.4% (280/567) 0.05
Clinical syndrome at presentation:
    ST-segment elevation MI >24 hours, n (%) 26.9% (32) 30.8% (177) 0.40
    Non-ST-segment elevation MI, n (%) 72.3% (86) 64.3% (370) 0.10
    Unstable angina, n (%) 0.8% (1) 4.9% (28) 0.04
Creatinine clearance (mL/min)* 95.4 [69.2, 122.9] 97.3 [77.8, 123.3] 0.50
HbA1c* 6.70 [6.20, 7.70] 5.60 [5.30, 6.00] <0.0001
Cardiac Medications
Any lipid lowering medication:
       At discharge, n (%) 88.2% (105) 88.5% (509) 0.93
       At 3 years, n (%) 87.4% (83/95) 88.1% (422/479) 0.84
Statins:
       At discharge, n (%) 84.0% (100) 85.9% (492/573) 0.61
       At 3 years, n (%) 83.2% (79/95) 84.7% (405/478) 0.7
Lipid lowering medication (non statin):
       At discharge, n (%) 11.8% (14) 8.9% (51) 0.32
       At 3 years, n (%) 12.6% (12/95) 13.2% (63/479) 0.89
Aspirin:
       At discharge, n (%) 98.3% (117) 96.5% (555) 0.40
       At 3 years, n (%) 92.6% (88/95) 91.4% (438/479) 0.70
Thienopyridines:
       At discharge, n (%) 96.6% (115) 97.0% (558) 0.77
       At 3 years, n (%) 45.3% (43/95) 33.2% (159/479) 0.02
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Table 1   Continued 
 
  Diabetes No Diabetes p-value
n=119 n=575
ACE inhibitors:
       At discharge, n (%) 71.2% (84/118) 61.0% (351) 0.04
       At 3 years, n (%) 62.1% (59/95) 56.4% (270/479) 0.30
Angiotensin receptor blocker:
       At discharge, n (%) 16.0% (19) 7.0% (40/572) 0.001
       At 3 years, n (%) 23.2% (22/95) 13.0% (62/477) 0.01
Beta blockers:
       At discharge, n (%) 91.6% (109) 90.4% (520) 0.69
       At 3 years, n (%) 81.1% (77/95) 81.0% (388/479) 0.99
Calcium channel blockers:
      At discharge, n (%) 21.4% (25/117) 11.2% (64/570) 0.003
      At 3 years, n (%) 21.5% (20/93) 12.6% (60/475) 0.02
*Median and interquartile range; CAD denotes coronary artery disease; MI denotes myocardial infarction; 
PCI denotes percutaneous coronary intervention; CABG denotes coronary artery bypass graft surgery.
Table 2   Patient-level non-culprit lesion  baseline IVUS findings in the  entire study 
population with and without diabetes 
 
  Diabetes No Diabetes p-value
n=119 n=575
Number of IVUS non-culprit lesions* 5 [4, 6] 5 [4, 6] 0.78
IVUS non-culprit lesions - volumetric data
Total lesion length (mm)* 68.85 [47.24, 
97.98]
73.31 [44.42, 
105.03]
0.81
Plaque volume (%) * 49.8 [47.0, 52.7] 49.1 [46.6, 52.0] 0.13
Prevalence of patients with ≥1 high-risk non-culprit lesion characteristic 
MLA ≤4 mm2, % (n) 61.9% (70/113) 53.9% (293/544) 0.12
PB ≥70%, % (n) 39.8% (45/113) 32.2% (175/544) 0.12
TCFA, % (n) 56.1% (60/107) 53.2% (266/500) 0.59
MLA ≤4 mm2 and PB ≥70%, % (n) 32.7% (37/113) 24.3% (132/544) 0.06
MLA ≤4 mm2 and TCFA, % (n) 36.3% (41/113) 27.6% (150/544) 0.06
PB ≥70% and TCFA, % (n) 24.8% (28/113) 17.6% (96/544) 0.08
All three high-risk characteristics, % (n) 21.2% (24/113) 13.6% (74/544) 0.04
*Median and interquartile range; IVUS denotes intravascular ultrasound; MLA denotes minimum lumen area; PB 
denotes plaque burden; TCFA denotes thin cap fibroatheroma.
86
Chapter 5
Table 3   Quantitative coronary angiography of the non-culprit lesions in the entire 
study population with and without diabetes 
 
  Diabetes No Diabetes p-value
Angiographic defined lesions n=316 n=1494
Reference vessel diameter (mm)* 2.23 [1.83, 2.83] 2.27 [1.88, 2.78] 0.54
Minimal lumen diameter (mm)* 1.43 [1.06, 1.88] 1.42 [1.07, 1.83] 0.82
Diameter stenosis (%)* 37.1 [31.6, 45.2] 37.5 [31.9, 46.6] 0.41
Lesions with QCA DS ≥50% 17.9% (54/302) 19.7% (281/1423) 0.46
Lesions with QCA DS ≥70% 4.0% (12/302) 4.3% (61/1423) 0.81
Thrombus 0.3% (1) 0.4% (6) 1.0
Eccentricity 5.7% (18) 4.6% (69) 0.41
Coronary artery lesion location
Left main 0.9% (3) 0.4% (6) 0.20
Left anterior descending (or branches) 38.9% (123) 40.2% (601) 0.67
Left circumflex (or branches) 30.4% (96) 31.1% (464) 0.81
Right (or branches) 29.7% (94) 28.3% (423) 0.61
IVUS defined lesions n=538 n=2561
Reference vessel diameter (mm)* 2.95 [2.54, 3.46] 3.03 [2.59, 3.51] 0.03
Minimal lumen diameter (mm)* 2.46 [2.03, 2.99] 2.55 [2.09, 3.06] 0.07
Diameter stenosis (%)* 13.3 [7.0, 23.2] 13.2 [6.9, 23.0] 0.93
Lesions with QCA DS ≥ 50% 2.0% (11) 1.6% (41) 0.47
Lesions with QCA DS ≥ 70% 0.2% (1) 0.0% (0) 0.17
Thrombus 0.2% (1) 0.4% (9) 1.0
Coronary artery lesion location
Left main 5.4% (29) 4.4% (113) 0.32
Left anterior descending (or branches) 30.9% (166) 33.1% (848) 0.31
Left circumflex (or branches) 25.5% (137) 26.4% (677) 0.64
Right (or branches) 38.3% (206) 36.0% (923) 0.32
*Median and interquartile range; QCA denotes quantitative coronary angiography; DS denotes diameter 
stenosis; IVUS denotes intravascular ultrasound.
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Table 5   Baseline clinical and IVUS characteristics in DM patients with or without TCFA 
 
  TCFA No TCFA p-value
n=43 n=39
Age, years, mean ± SD 60.9 ± 12.6 62.9 ± 9.7 0.49
Male, n (%) 76.7% (33) 76.9% (30) 0.98
Diabetes mellitus, n (%) 100.0% (43) 100.0% (39) N/A
    Insulin-treated, n (%) 7.0% (3) 17.9% (7) 0.18
Prior MI, n (%) 4.7% (2) 12.8% (5) 0.25
History of known CAD (stenosis ≥50%), n (%) 9.3% (4) 17.9% (7) 0.25
Family history of CAD, n (%) 32.6% (14) 35.9% (14) 0.75
Hypertension, n (%) 58.1% (25) 56.4% (22) 0.87
Hypercholesterolaemia, n (%) 58.1% (25) 56.4% (22) 0.87
Smoking, n (%) 53.5% (23) 30.8% (12) 0.04
Clinical syndrome at presentation:
    ST-segment elevation MI >24 hours, n (%) 37.2% (16) 25.6% (10) 0.26
    Non-ST-segment elevation MI, n (%) 60.5% (26) 74.4% (29) 0.18
    Unstable angina, n (%) 2.3% (1) 0.0% (0) 1.0
Creatinine clearance (mL/min)* 99.4 [83.2, 131.3] 92.5 [68.7, 121.3] 0.29
HbA1c* 6.50 [6.15, 8.25] 6.70 [6.20, 7.70] 0.85
IVUS non-culprit lesions
Number of IVUS non-culprit lesions* 5 [4,6] 5 [4,6] 0.53
IVUS non-culprit lesions- volumetric data
Total lesion length (mm)* 78.65
[59.79, 102.18]
48.82
[32.95, 81.28]
<0.01
Plaque volume (%)* 50.0
[47.7, 52.9]
48.3
[46.1, 50.4]
0.03
Prevalence of patients with >1 high-risk non-culprit lesion characteristic
MLA ≤4 mm2, % (n) 65.1% (28) 48.7% (19) 0.13
PB ≥70%, % (n) 48.8% (21) 28.2% (11) 0.06
*Median and interquartile range; CAD denotes coronary artery disease; MI denotes myocardial infarction; 
PCI denotes percutaneous coronary intervention; CABG denotes coronary artery bypass graft surgery; IVUS 
denotes intravascular ultrasound; MLA denotes minimum lumen area; PB denotes plaque burden. MLA 
denotes minimum lumen area; PB denotes plaque burden.
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Table 6   Baseline clinical and IVUS characteristics in Non DM patients with or  
without TCFA 
 
  TCFA No TCFA p-value
n=42 n=40
Age, years, mean ± SD 60.4 ± 11.8 61.5 ± 10.2 0.76
Male, n (%) 73.8% (31) 82.5% (33) 0.34
Prior MI, n (%) 12.2% (5) 7.5% (3) 0.48
History of known CAD (stenosis ≥50%), n (%) 14.6% (6) 12.8% (5) 0.81
Family history of CAD, n (%) 40.5% (17) 25.0% (10) 0.14
Hypertension, n (%) 47.6% (20) 62.5% (25) 0.18
Hypercholesterolaemia, n (%) 66.5% (28) 47.5% (19) 0.08
Smoking, n (%) 45.2% (19) 32.5% (13) 0.24
Clinical syndrome at presentation:
    ST-segment elevation MI >24 hours, n (%) 28.6% (12) 22.5% (9) 0.53
    Non-ST-segment elevation MI, n (%) 71.4% (30) 72.5% (29) 0.91
    Unstable angina, n (%) 0.0% (0) 5.0% (2) 0.14
Creatinine clearance (mL/min)* 94.3 [73.5, 120.6] 85.9 [64.0, 101.4] 0.12
IVUS non-culprit lesions
Number of IVUS non-culprit lesions* 6 [5,7] 5 [3,6] 0.02
IVUS non-culprit lesions- volumetric data
Total lesion length (mm)* 103.16
[75.26, 119.07]
58.63
[25.85, 84.03]
<0.01
Plaque volume (%)* 49.4
[46.7, 52.6]
49.0
[46.4, 52.5]
0.78
Prevalence of patients with >1 high-risk non-culprit lesion characteristic
MLA ≤4 mm2, % (n) 61.9% (26) 52.5% (21) 0.39
PB ≥70%, % (n) 47.6% (20) 32.5% (13) 0.16
*Median and interquartile range; CAD denotes coronary artery disease; MI denotes myocardial infarction; 
PCI denotes percutaneous coronary intervention; CABG denotes coronary artery bypass graft surgery; IVUS 
denotes intravascular ultrasound; MLA denotes minimum lumen area; PB denotes plaque burden. MLA 
denotes minimum lumen area; PB denotes plaque burden.
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Abstract
Background: Fractional Flow Reserve (FFR) is a widely used tool for the identification of 
ischaemia-generating stenoses and to guide decisions on coronary revascularisation. 
However, the safety of FFR-based decisions in high-risk subsets, such as patients with 
Diabetes Mellitus (DM) or vulnerable stenoses presenting thin-cap fibro-atheroma (TCFA), 
is unknown. This study will examine the impact of optical coherence tomography (OCT) 
plaque morphological assessment and the identification of TCFA, in combination with FFR 
to better predict clinical outcomes in DM patients. 
Methods: COMBINE (OCT-FFR) is a prospective, multi-centre study investigating the 
natural history of DM patients with ≥1 angiographically intermediate target lesion in three 
subgroups of patients; patients with FFR negative lesions without TCFA (group A) and 
patients with FFR negative lesions with TCFA (group B)) as detected by OCT and to 
compare these two groups with each other, as well as to a third group with FFR-positive, 
PCI-treated intermediate lesions (group C). The study hypothesis is that DM patients with 
TCFA (group B) have a worse outcome than those without TCFA (group A) and also when 
compared to those patients with lesions FFR ≤0.80 who underwent complete revascular-
isation. The primary endpoint is the incidence of target lesion major adverse cardiac 
events (MACE); a composite of cardiac death, myocardial infarction or rehospitalisation for 
unstable/progressive angina in group B vs. group A. 
Conclusion: COMBINE (OCT-FFR) is the first prospective study to examine whether the 
addition of OCT plaque morphological evaluation to FFR haemodynamic assessment of 
intermediate lesions in DM patients will better predict MACE and possibly lead to new 
revascularisation strategies.
Trial Registration: Netherlands Trial Register: NTR5376
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Introduction
Diabetes Mellitus (DM) is associated with more rapidly progressive coronary atherosclerosis 
and increased mortality compared to non-diabetic patients[1, 2]. Fractional Flow Reserve 
(FFR) is a pressure-derived intracoronary functional index currently recommended in 
clinical practice guidelines for stenosis assessment in the absence of objective evidence 
of myocardial ischaemia [3]. Previous studies have shown that FFR-negative lesions (FFR 
>0.80) can be safely treated medically, while FFR-positive lesions (FFR ≤ 0.80) benefit 
from revascularisation[4, 5]. However, in the majority of the FFR trials performed to date, 
the percentage of DM patients is low[4-6].
More recently, several studies have suggested that FFR-based revascularisation may not 
be associated with the same reduction in adverse cardiac events as seen in non-DM 
patients[7-10], even when the presence of microvascular disease, which might imply 
ischaemia of non-obstructive origin, is taken into consideration[10]. These findings could 
be explained by the fact that, in patients with DM,  adverse cardiac events after ischaemia- 
driven revascularisation may be related to the presence of more active atherosclerotic 
disease, resulting in subsequent acute coronary events or obstructive disease progression, 
rather than to ischaemic burden at the time of revascularisation[11, 12]. However, this 
hypothesis of more rapid atherosclerosis progression in high risk plaque, is as yet only 
postulated.
The PROSPECT study demonstrated an ~12% 3-year rate of future unanticipated major 
adverse cardiovascular events (MACE) in non-culprit lesions (NCL)[13]. Furthermore, insulin 
dependent DM was identified as an independent predictor of NCL MACE, in addition to 
the presence of thin-cap fibroatheroma (TCFA), minimal lumen area (MLA) ≤ 4mm2, and a 
plaque burden ≥70%. Additionally, the rate of future NCL-related MACE was twice as high 
among patients with DM hosting at least one thin-cap fibroatheroma TCFA, whereas 
those DM patients without a TCFA had a more benign prognosis, similar to non-DM 
patients[14].  
Although these NCL’s appeared angiographically mild, significant differences in plaque 
composition between those patients with versus without DM were noted[15]. Separately, 
Kato et al have shown that the incidence of TCFA in patients with DM is higher than in 
patients without DM[16]. As FFR was not measured in PROSPECT, whether these lesions 
were truly non-ischaemic is unknown, however given the mild angiographic severity 
(diameter stenosis; median 36.2% IQR [31.1, 44.2]) this was unlikely. Nonetheless, it has 
been shown that these high risk IVUS-detected plaque features have no correlation with 
FFR functional significance of intermediate coronary lesions, and so whether ischaemia is 
the only factor in the prediction of future adverse cardiac events is questionable[17]. 
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Several studies using intravascular ultrasound (IVUS), have attempted to address the 
mismatch between the functional and anatomical significance of intermediate coronary 
lesions, however these have largely focused on quantitative assessments of MLA, lesion 
length and plaque burden. From these studies, it has been shown that only a mere 
moderate correlation between IVUS quantitative measurements and FFR exists[17-19]. 
Optical Coherence Tomography (OCT) is an intravascular imaging modality that provides 
a spatial resolution 10 times higher than IVUS([20]. Whilst OCT is superior to IVUS in 
identifying the haemodynamic significance of coronary stenoses, particularly in vessels 
<3 mm, its low specificity and only modest diagnostic efficacy precludes its use as a 
substitute for FFR functional stenosis assessment[21]. However, the true benefit of OCT 
may centre upon its superior ability to detect high risk vulnerable plaque.  With the 
introduction of OCT, our understanding of plaque morphology and the mechanisms of 
plaque rupture which result in ACS have been significantly advanced[22, 23]. A thin fibrous 
cap overlying a lipid-rich necrotic core is believed to be the substrate for most vulnerable 
plaques, and OCT is the only imaging modality that currently can accurately assess fibrous 
cap thickness[24]. Multiple intravascular imaging studies have shown the the presence of 
vulnerable plaque characteristics are more prevalent in DM patients compared to non-DM 
patients and in particular a greater burden of TCFA lesions[25-28]. Due to these character-
istics, OCT is being frequently used to evaluate lesion morphology, however, the predictive 
value of this modality with regard to future MACE is not well studied. 
In the COMBINE (OCT-FFR) study, we propose to investigate the incremental value of OCT 
plaque morphological evaluation added to FFR haemodynamic assessment of inter - 
mediate lesions in DM patients in predicting MACE when following an ischaemia-driven 
 revascularisation strategy.
Study Design and Objectives
The COMBINE (OCT-FFR) is a prospective multi-centre, international study, involving 
centres in the Netherlands, Germany, Spain, Italy, Switzerland and Poland. The study was 
approved by the Institutional Review Board of each participating hospital. The study is 
registered on the Netherlands Trial Registry under the identifier NTR5376[29].
The primary objective of the COMBINE (OCT-FFR) study is to evaluate whether the presence of 
certain plaque characteristics considered to carry a high-risk (such as TCFA) in lesions with 
an intermediate-severe angiographic stenosis but which are non-ischaemic (FFR >0.80) 
can predict future adverse cardiac events. For this purpose, we have selected to examine 
only patients with DM, as these patients constitute the sub-population with the fastest 
progression of coronary atherosclerosis and where recent evidence suggests that deferred 
revascularisation based upon FFR assessment may not be as safe as in non-DM patients.  
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The study design is illustrated in Figure 1. The study population consists of all DM patients 
with any clinical presentation who undergo FFR assessment in lesions with an intermediate- 
severe angiographic stenosis. Lesions which are determined as the culprit lesion in 
myocardial infarction will not be included, owing to the lack of evidence for FFR in such 
clinical scenarios. FFR will be performed according to standard protocol using the 
PressureWire Aeris™ or Certus™ wires, St Jude Medical, St Paul, Minnesota, USA. Adenosine 
is the preferred hyperaemic agent to be administered via the intravenous route at a 
recommended dose of 140μg/kg/min to achieve maximum hyperaemia. Should 
intracoronary adenosine be administered, a dose of 40µg for the right coronary artery 
and 80µg for the left coronary artery is recommended. Once steady-state maximum 
hyperaemia is achieved, FFR is calculated as the ratio of mean distal intracoronary pressure 
measured by the pressure wire, and the mean arterial pressure measured through the 
coronary guiding catheter.  In all patients where FFR is performed, OCT assessment using 
the frequency domain Dragonfly™ OCT system, St Jude Medical, St Paul, Minnesota, USA will 
also take place. Patients with ≥1 lesion which does not undergo revascularisation based 
upon a FFR negative (>0.80) assessment will be followed clinically. Depending upon the 
OCT findings, patients without any TCFA (see appendix for definition) lesions will form 
Group A, whilst patients with ≥1 TCFA carrying lesion will form Group B. Finally, patients 
hosting only FFR-positive target lesions and no other remaining lesions, which have 
undergone complete index revascularisation either by PCI or CABG will form Group C. 
Study Endpoints
Primary Endpoint: the per patient incidence of target lesion(s) related composite 
MACE defined as: Cardiac death, myocardial infarction (MI), clinically-driven target lesion 
 revascularisation (TLR) or hospitalisation due to unstable or progressive angina at 18 months 
in the FFR-negative No-TCFA patients (Group A) as compared to the FFR-negative TCFA 
patients (Group B).
Major Secondary Endpoints: 
1. The per patient incidence of the target lesion(s) related composite MACE: Cardiac 
Death, MI, clinically-driven TLR or hospitalisation due to unstable or progressive 
angina between FFR-negative TCFA-positive patients (Group B) and the group of 
patients with PCI-treated FFR-positive lesions (Group C). 
2. The per patient incidence composite MACE: Cardiac death, MI, any clinically-driven 
revascularisation or hospitalisation due to unstable or progressive angina between 
FFR- negative TCFA (Group B) and the group of patients with PCI-treated FFR-positive 
lesions (Group C). 
3. The incidence of MACE (Cardiac Death, MI, clinically-driven revascularisation or 
 hospitalisation due to unstable or progressive angina) in patients carrying any non- 
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revascularised TCFA lesion (target or elsewhere within the assessed coronary segments) 
compared to patients without any identified TCFA lesions.  
Additional Secondary Endpoints:
1.  The incidence of the separate components of the primary endpoint at 18 months 
between Group A and Group B. 
2.  The incidence of FFR positive (≤0.80) lesions in angiographically mild lesions (<50% 
diameter of stenosis) and their rate clinical outcomes at 18 months 
3.  The incidence of cardiac death, MI and and clinically-driven target vessel revascularisation 
(TVR) at 18 months. 
4.  Clinical predictors of MACE at 18 months in patients with ≥1 FFR >0.80 lesion. 
5.  Outcome of MACE in older versus younger patients (cut-off 75 years) with ≥1 FFR 
>0.80 lesion.
6.  Impact of HbA1c on the incidence of TCFA and MACE outcomes 
7.  The incidence of target lesion related MACE at 18 months in the FFR- negative TCFA 
negative patients (Group A) vs. patients with PCI treated FFR + lesions with no other 
remaining lesions (Group C). 
8.  The incidence of target lesion related MACE at 18 months in FFR-negative lesions in 
patients with versus without ACS at presentation. 
9.  The impact of renal insufficiency (eGFR<60mls/min) on the incidence of TCFA and 
MACE outcomes 
10.  The impact of gender on the incidence of TCFA and MACE outcomes 
11.  The per patient incidence of the target lesion(s) related composite MACE defined as 
Cardiac Death, MI, clinically-driven TLR or hospitalisation due to unstable or progressive 
angina in the FFR-negative No-TCFA (Group A) and FFR- negative TCFA (Group B) at 
3 years (if funding permits). 
12.  The incidence of a composite endpoint of Cardiac Death, MI, clinically-driven TLR or 
hospitalisation due to unstable or progressive angina between FFR-negative TCFA 
(Group B) and the group of patients with PCI treated FFR + lesions with no other 
remaining lesions (Group C) at 3 years (if funding permits). 
13.  The impact of MI (prior or at presentation) on the incidence of TCFA and MACE outcomes
14.  The impact of other OCT-detected plaque types (other than TCFA) on the incidence of 
MACE in Group A and Group B. 
Follow-up data collection and study management
Patient demographics and clinical data at inclusion are collected online in an electronic 
database (CRO Diagram, Zwolle, The Netherlands). The first 2 patients included in all 
centres will be fully monitored to identify inconsistent data. Upon discharge and after the 
intended follow-up period of 18 months, data will be collected at visits at outpatient 
clinics or, if not feasible, by telephone follow-up and/or a medical questionnaire, carried 
98
Chapter 6
out by staff who are blinded. Follow-up beyond 18 months is intended, should funding 
permit. During visits and telephone calls, patients will be interviewed regarding repeat 
hospitalisations, revascularisation procedures, and myocardial infarction (MI) during 
follow-up. In case of death, information will be obtained from the patient’s medical chart, 
local institution and by contact where required with the patient’s cardiologist/general 
practitioner. FFR and OCT core laboratory will be based at an external independent 
research centre, in addition to overall trial coordination, data management and study 
monitoring (CRO Diagram, Zwolle, the Netherlands). An independent clinical events 
committee will adjudicate all potential clinical endpoints.
Sample size 
Whilst an observational study, without randomisation, in order to confer meaning to the 
results derived, a power calculation has been made to estimate a projected number of 
patients that would allow observation of meaningful differences in MACE rates between 
the above mentioned subgroups of patients. The primary endpoint event rate at 18 months in 
the A and B group respectively are assumed to be 5 % and 20% respectively. Furthermore, 
we assume that 1/3 of the patients will have at least one lesion with a positive FFR (£0.80) 
as shown from the major FFR trials[4, 5].
Table 1   COMBINE OCT-FFR inclusion and exclusion criteria 
 
Inclusion criteria:
Age ≥ 18 years
History of DM with any indication for angiography (Stable Angina Pectoris or any type of ACS)
At least ≥ 1 de novo target lesion in a native coronary segment with a visually estimated 
diameter stenosis of between ≥40% and ≤80%
Exclusion criteria:
TIMI flow <3 in the target lesion(s)
Target lesion reference diameter <2.0mm
Left Ventricular ejection fraction <30%
Malignancy
Life expectancy <2years
Unwilling or unable to provide informed consent
DM denotes Diabetes Mellitus; ACS denotes Acute Coronary Syndrome; TIMI denotes thrombolysis in myocardial 
infarction
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An equal distribution of patients between subgroups A and B is expected (50% in each 
group) however the power calculation takes in account variations up to 20 % (i.e. an 
unequal TCFA distribution in both directions up to 30% vs. 70%). Taking into account an 
expected loss in follow-up of 7%, a total of 500 patients enrolled in the study will provide 
80% power to reject the null hypothesis with 5% type I error. With this number of patients, 
it is expected that this study is also powered to assess its major secondary endpoint if an 
equal distribution (in groups A and B) is observed and the target lesion MACE rate in the 
group C does not exceed 7% (assumption based on observations from recent novel 
drug-eluting stent (DES) studies for non-complex lesions[30]. 
Statistical Analysis
In general, statistics for continuous variables will include mean, median, standard 
deviation, minimum, maximum, and sample size for each treatment group, and two-sided 
95% confidence intervals of the mean difference between the treatment groups. Binary 
variables will be described with frequencies, percentages, and two-sided 95% confidence 
intervals of the difference in percentages between treatments using exact methods. For 
time-to-event data, Kaplan-Meier estimates at the indicated time points will be displayed 
along with 95% confidence intervals for the difference in the estimates along with log rank 
test results. In addition, survival curves will be constructed for all time to event secondary 
endpoints using Kaplan-Meier methods. For the primary endpoint as for the secondary 
endpoint a multivariate regression analysis will be performed. 
Present Status
The COMBINE (OCT-FFR) study started enrolment in April 2015; and as of August 1, 2016, 
148 patients have been included. To date 12 participating centres are actively enrolling, 
and several others are still in the start-up process. End of the enrolment is expected in 
2017.
The COMBINE (OCT-FFR) study is investigator driven and is supported by an unrestricted 
grant from St. Jude Medical. The authors are solely responsible for the design and conduct 
of this study, all study analyses, and drafting and editing of the manuscript. 
Conclusion
COMBINE (OCT-FFR) is the first large prospective natural history study to examine whether 
the addition of OCT plaque morphological evaluation and the identification of high-risk 
plaque features such as TCFA, in combination with FFR haemodynamic assessment in DM 
patients will better predict MACE and possibly lead to new revascularisation strategies in 
a group of patients at high risk for future adverse cardiac events. 
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Abstract
Diabetes Mellitus (DM) is associated with an excess in cardiovascular morbidity and 
mortality, and is characterised by an increased rates of coronary artery disease. Furthermore, 
once atherosclerosis is established, this is associated with increased extent, complexity 
and a more rapid progression than seen in non-DM patients. Ischaemia is the single most 
important predictor of future hard cardiac events and ischaemia correction remains the 
cornerstone of current revascularisation strategies. However recent data suggests that, in 
DM patients, coronary atherosclerosis despite the absence of ischaemia, detected by 
either invasive or non-invasive methods, may not be associated with the same low risk of 
future cardiac events as seen in non-DM patients. This review seeks to examine the current 
evidence supporting an ischaemia driven revascularisation strategy, and to challenge the 
notion that ischaemia is the only clinically relevant factor in the prediction of cardiovascular 
outcomes in all-comer DM patients. Specifically, we examine whether in DM patients’ 
certain characteristics beyond ischaemia, such as microvascular disease, coronary athero-
sclerosis burden, progression and plaque composition, may need to be considered for a 
more refined risk stratification in these high-risk patients.
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Introduction
An estimated 415 million people worldwide have diabetes mellitus (DM), with the 
prevalence expected to increase by a further 50% by 2050[1]. DM is associated with an 
excess in morbidity and mortality [2].  Compared to patients without DM, people with DM 
are between two and four times more likely to have cardiovascular disease (CVD), with 
CVD accounting for a large proportion of the excess mortality related to diabetes[3-7]. 
Indeed, 5-year cardiovascular mortality rates amongst those DM patients without a history 
of coronary artery disease (CAD) are similar to those of non-DM patients with a history of 
previous MI, and as such DM is considered as a CAD equivalent[8]. 
Furthermore, once atherosclerosis is established, it is associated with increased rates, 
extent, complexity and more rapid progression than seen in non-DM patients, with 
resultant poor outcomes[9-11].  In addition, revascularisation outcomes in DM patients 
treated with PCI continue to be less favorable than in non-DM patients[12]. Despite 
refinements in stent design over the past number of years which have reduced rates of 
target lesion revascularisation (TLR), major adverse cardiac events (MACE) and stent 
thrombosis in non-DM patients, regrettably these improvements have not been 
transferred to DM patients, particularly those with more complex lesions[12, 13]. 
Alternatively, DM patients with non-complex lesions appear to have similar outcomes to 
non-DM patients, and so the earlier identification of these patients may improve outcomes 
and arrest progression[13]. This is particularly salient as for those DM patients with 
multi-vessel disease, current evidence favors coronary artery bypass grafting (CABG) as 
the preferred revascularisation modality, which is likely to reflect the more complete 
 revascularisation and global protection provided by arterial conduits against rapid athero-
sclerosis progression in PCI and untreated segments.
The PROSPECT (Providing Regional Observations Study Predictors of Events in the 
Coronary Tree) study and subsequent sub-study analyses have consistently highlighted 
DM to be associated with worse outcomes. These worse outcomes in DM patients 
originated not only from the culprit lesion but also from non-culprit lesions (which were 
of very mild angiographic severity at baseline).  Furthermore, patients with DM were more 
likely to have at least one non-culprit lesion containing multiple high-risk plaque features 
shown to correlate with future unanticipated cardiac events[14, 15]. Thus, angiographical-
ly mild but otherwise “high risk” lesions in DM patients may not be as quiescent as in 
non-DM patients and so whilst presently the most appropriate revascularisation strategy 
is based on targeting only those lesions causing ischaemia, whether this is the only factor 
in DM patients is questionable[13, 16-18]. This review seeks to examine the current 
evidence supporting an ischaemia driven revascularisation strategy, and to challenge the 
notion that ischaemia is the only clinically relevant factor in the prediction of cardio- 
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vascular outcomes in all-comer DM patients. Specifically we examine whether in DM 
patients, certain characteristics beyond ischaemia, such as microvascular disease, coronary 
 atherosclerosis burden, progression and plaque composition, may need to be considered 
for a more refined risk stratification in these high-risk patients. 
The Importance of ischaemia
Studies have repeatedly shown that ischaemia is the most important predictor of 
outcomes, with the presence of ischaemia being associated with a 12-fold increased risk 
of future adverse cardiac events (death or non-fatal myocardial infarction) compared to 
those patients without ischaemia[19]. Furthermore, the presence of moderate to severe 
ischaemia is associated with a significantly higher risk of subsequent adverse events 
including death or myocardial infarction compared with mild or no ischaemia[20]. In 
keeping with this, the Clinical Outcomes Utilising Revascularisation and Aggressive Drug 
Evaluation (COURAGE) nuclear sub-study showed that those patients with the largest 
burden of ischaemia, as detected by single-photon emission computed tomography 
(SPECT), derived the greatest benefit from revascularisation[21]. Conversely, worsening of 
ischaemia is an independent predictor of death or myocardial infarction[22], underscoring 
the concept of ischaemia driven revascularisation, whether by percutaneous coronary 
intervention (PCI) or coronary artery bypass grafting (CABG)[23-25]. Specifically in DM patients, 
it has been shown that incomplete revascularisation is associated with substantially worse 
outcomes, particularly in those patients with a large residual burden of ischaemia[26, 27]. 
Fractional Flow Reserve and the assessment of ischaemia
In the catheterization laboratory, fractional flow reserve (FFR) has emerged as the gold- 
standard invasive technique to detect coronary stenoses of sufficient haemodynamic 
severity to induce myocardial ischaemia. Given the poor correlation between angiographic 
severity and ischaemic significance, the use of FFR to reliably detect functionally significant 
lesions-which may otherwise be left untreated with poor resultant outcomes- seems logical 
and appealing[28]. Conversely, FFR may also identify those lesions which despite angiographic 
appearances are not functionally significant and do not require revascularisation. 
In the DEFER study, intermediate coronary stenoses which were non-ischaemic (FFR >0.75 
cut off) had a low risk of future adverse cardiac events; approximately 1% per year and this 
risk was not decreased by revascularisation[29]. Additionally, at 5-year follow-up, 
non-ischaemic lesions continued to have significantly better outcomes compared to 
those lesions which were FFR<0.75 and had index revascularisation (5-year event rate; 
3.3% vs 15.7%, p=0.002).  Subsequently, the Fractional Flow Reserve Versus Angiography in 
Multi-vessel Evaluation (FAME) trial, enrolled 1005 patients with multi-vessel CAD who 
were randomized to undergo PCI with drug-eluting stents guided by angiography alone 
or guided by FFR assessment of ischaemia[30].  Patients assigned to FFR-guided PCI 
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underwent stenting of indicated lesions only if the FFR was ≤0.80. The primary end-point 
was the rate of death, nonfatal myocardial infarction, and repeat revascularisation at 
1 year, and was 18.3% in the angiography group versus 13.2% in the FFR group (p=0.02). 
In keeping with the DEFER study, those lesions which were found to be non-ischaemic, 
had excellent outcomes with medical therapy alone; 2-year rate MI 0.2%, 1.9% revascular-
isation rate. Thus, based on these studies, limiting PCI to only ischaemia inducing lesions 
resulted in significantly better results and deferred revascularisation of non-ischaemic 
lesions was associated with excellent outcomes, in addition to significant cost savings[31]. 
Moreover, similar to non-invasive studies, the FAME II study has shown that those lesions 
which are ischaemia inducing and which are not revascularised, have substantially higher 
adverse event rates compared to similar angiographic lesions which are non-ischaemic, 
whereas revascularisation reduces this risk[32]. The combination of these studies have 
shaped current guidelines, recommending FFR to identify the haemodynamic relevance 
of intermediate coronary lesions and deferred revascularisation of those lesions FFR 
>0.80[25].  Unfortunately, the proportion of patients with DM included in these studies is 
low, ranging from 10.8-27%, and thus the concept of FFR guided revascularisation in a 
population of only DM patients has perhaps not been completely proven. 
FFR and Diabetes Mellitus 
DM is characterised by insulin resistance and chronic hyperglycaemia, and concerns 
regarding increased vascular resistance and reduced vasodilative capacity due to chronic 
hyperglycaemia have been raised[33]. Whilst, the reliability of FFR in DM patients is now 
accepted, more recently data has emerged suggesting that FFR and specifically the 
deferral of revascularisation based upon a FFR >0.80 in DM patients may not be associated 
with the same low risk of adverse events as seen in non-DM patients[34]. 
Our group have recently shown that compared to those DM patients who undergo 
complete revascularisation, DM patients with ≥1 remaining FFR negative (>0.80) lesion, 
have a significantly higher incidence of major adverse cardiac events (MACE), including 
death/MI, rehospitalisation for acute coronary syndrome (ACS) and target lesion revascu-
larisation (TLR), HR 2.01 (95% CI; 1.21-3.33, p<0.01)[35]. Furthermore, significant clustering of 
MACE events in those DM patients with a previous MI carrying FFR negative lesions was 
noted, whereas those patients without a previous MI had much more benign outcomes 
(Figure 1). In a separate study, comparing deferred revascularisation based upon a 
FFR>0.80 in 122 DM patients and 128 non-DM patients, DM patients had significantly 
higher rates of target lesion failure (TLF), HR 3.65 (95% CI; 1.40-9.53, p<0.01), with significantly 
higher rates of target lesion revascularisation (TLR) and a clear trend towards a higher 
incidence of target vessel MI (Figure 2)[36]. Conversely in non-DM patients, deferred revas-
cularisation appeared to be as safe as reported in prior studies, with low rates of future 
108
Chapter 7
target vessel MI and TLR. Recently, Liu et al have confirmed these findings and have shown 
that amongst those patients with an FFR>0.85, diabetics had a more than two-fold higher 
risk of death and MI than non-diabetics, HR 2.20 (95%CI; 1.19-4.01, p=0.015)[37]. In addition, 
this study also reported that among non-diabetic patients with deferred PCI based upon 
a FFR>0.80, higher FFR values (closer to 1.0) were associated with lower rates of death, MI 
and revascularisation. However, in DM patients with deferred revascularisation, FFR values 
were unable to differentiate the risk of cardiovascular events, a finding we have recently 
confirmed, showing that FFR values do not predict future deferred lesion failure in FFR 
negative lesions in DM patients. Moreover, using multi-variate analysis, the only independent 
predictors of lesion failure identified were insulin requiring DM and a history of prior 
 revascularisation, both conditions marked by more rapid atherosclerosis progression[38].
Figure 1   Time-to-event estimates for MACE, in FFR(-)MT and FFR(+)CR groups according 
to presence or absence of prior MI
MACE denotes Major Adverse Cardiac Event; MI denotes Myocardial Infarction; FFR denotes 
Fractional Flow Reserve; FFR(-)MT denotes the group of patients with ≥1 FFR negative (FFR>0.80) 
lesion(s) which underwent medical therapy; FFR(+)CR denotes the group of patients with all lesions 
FFR positive (FFR≤0.80) and had complete revascularisation; HR denotes Adjusted Hazard Ratio.
Reproduced with permission from Kennedy et al [35]
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Thus, in all of these studies, deferred revascularisation in DM patients based upon the 
absence of FFR detected ischaemia does not appear to be as safe as in non-DM patients. 
Several possible mechanisms, such as an increased prevalence of microvascular dysfunction, 
more aggressive atherosclerosis progression, an increased burden of disease and a more 
active and high-risk plaque composition may contribute to this elevated risk of adverse 
cardiac events despite the absence of ischaemia. 
Complementary haemodynamic assessments and microvascular disease
Whilst FFR provides assessment of epicardial coronary stenosis severity and lesion-level 
ischaemia, clinical events occur even in patients with FFR>0.80, with one possible 
explanation owing to abnormalities in microvasculature. Coronary flow reserve (CFR) and 
the index of microcirculatory resistance (IMR) may provide additional complementary 
information in such situations. Indeed, significant discordance, ranging from 27% to 40%, 
has been described between FFR and CFR measurements[39, 40].  In a study by Meuwissen 
Figure 2   Time-to-event estimates for Target Lesion Failure according to FFR(-)DM and 
FFR(-)NonDM groups
TLF denotes Target Lesion Failure; CI denotes Confidence Interval; HR denotes Hazard Ratio 
(adjusted for age); FFR denotes Fractional Flow Reserve; FFR(-)DM denotes the group of DM 
patients with FFR negative (FFR>0.80) lesions; FFR(-)NonDM denotes the group of Non-DM 
patients with FFR negative (FFR>0.80) lesions.
Reproduced with permission from Kennedy et al [36]
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et al, in patients undergoing combined FFR and CFR assessment, approximately 10% of 
intermediate lesions when assessed as FFR non-ischaemic, have an abnormal CFR defined 
as <2.0, a finding confirmed by others[41]. Recently, van de Hoef et al have shown that in 
those patients in whom a FFR>0.80 is associated with an abnormal CFR (<2.0), the clinical 
outcomes are significantly worse than in patients with intact microcirculation[42]. 
Microvascular disease and DM
Data from prior studies which have assessed the microcirculatory function in patients with 
and without DM, have shown that patients with DM have substantially altered 
microvascular function and even amongst those DM patients without known coronary 
artery disease (CAD), the presence of an abnormal coronary flow reserve (CFR) is associated 
with poor outcomes, comparable to non-DM patients with known CAD[43, 44]. 
Furthermore, it has been demonstrated that in diabetic patients without obstructive CAD, 
coronary microvascular function is substantially more impaired than in non-DM patients 
when matched for traditional cardiovascular risk factors[45]. Finally, in the The Prediction 
of CK-MB RElease During Successful Stenting Correlating with Indicators of Microvascular 
ObstruCTion (PREDICT) trial, despite similar pre-PCI FFR values, DM patients after PCI, had 
significantly lower CFR measurements indicative of greater microvascular dysfunction[46]. 
It has been postulated that this microvascular dysfunction promotes the process of ath-
erosclerosis. Indeed, this dysfunction is substantially worse in patients with poorer 
glycaemic control and may contribute to the poorer outcomes seen in such patients[47].
Recently Lee et al, examined the clinical, angiographic, and haemodynamic characteristics 
of patients with high FFR (>0.80) and evaluated the prognostic implications of abnormal 
CFR and IMR in these patients[48]. Despite similar clinical and angiographic characteristics, 
including similar Gensini and SYNTAX scores (to quantify patients’ macrovascular disease 
burden), patients with a high FFR, a low CFR and a high IMR had a significantly higher 
adverse event rate during follow-up compared with those patients with intact microcircu-
lation, HR: 5.623 (95% CI: 1.234-25.620; p=0.026)(Figure 3). Moreover, in a multivariate 
model comprising those patients with a high FFR, low CFR and high IMR, DM was identified 
as an independent predictor of adverse events, HR 2.71 (95%CI; 1.05–7.02, p= 0.04). 
Conversely, those patients with a high FFR and normal microvascular function (high CFR, 
low IMR) had excellent outcomes. Thus, based upon this study, abnormal microvascular 
function may in part explain the worse outcomes in DM patients despite the absence of 
FFR detected ischaemia, as has been recently described in several studies[35-37]. Whether 
the addition of complementary haemodynamic assessments in DM patients with negative 
FFR assessments, may result in a more accurate deferred revascularisation needs to be 
studied in larger dedicated studies and the development of repeatable methods of 
absolute coronary flow measurement may finally help to provide a better understanding 
of coronary microcirculation[49]. 
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Coronary atherosclerosis progression
Coronary atherosclerosis is a generalised disease and the natural history of CAD is that of 
a progressive condition, thus initially non-obstructive and non–ischaemia producing 
lesions can over time progress to become high-grade stenoses, resulting in cardiac events. 
Several studies have attempted to assess the impact of atherosclerosis progression on 
future events- Glaser et al, reported that 6% of initially non-culprit coronary lesions will 
have clinical plaque progression requiring non–target-lesion PCI by 1 year[50]. Chacko et 
al, provided 5-year follow-up data from the SIRIUS (Sirolimus-Eluting Stent in De Novo 
Native Coronary Lesions) trial, and have shown that events attributed to the non-target 
vessel are frequent and accounted for the majority of all adverse outcomes, with almost 
25% of patients suffering an event related to disease progression during the 5-year 
follow-up period in both the sirolimus and bare metal stent groups[51]. Finally, the 
contribution of atherosclerosis progression on future events may be even higher; based 
Figure 3   Clinical Outcomes According to Patterns of Microvascular Status Defined 
According to CFR and IMR Among Patients With High FFR
The cumulative incidence of patient-oriented composite outcomes was compared among 4 groups 
divided according to CFR and IMR. All IMR values were adjusted with Yong’s formula (IMRcorr). 
NA=not available; CFR denotes Coronary Flow Reserve; IMR denotes Index of Microvascular 
Resistance; CI denotes Confidence Interval.
Reproduced with permission from Lee et al [48]
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upon the results of the BASKET-PRO study, 40% of all events at 5 years and almost 40% of 
all new perfusion defects in patients without events were as a result of disease progression 
in non-target areas[52].
Atherosclerosis progression and DM
DM is associated with even more unremitting and rapidly progressive atherosclerosis 
progression, which may be as a result of numerous factors; hyperglycaemia induced 
endothelial dysfunction, increased platelet aggregation, and plaque instability. 
Additionally when these processes are combined with other traditional risk factors, a 
synergistic effect occurs which significantly accelerates atherosclerosis progression. In the 
Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial, diabetic patients 
had a 33% increase over non-diabetic patients in new lesion formation over a nine month 
follow up[53]. In the SWISSI II study, despite comprehensive cardiovascular risk factor 
intervention, DM was identified as the strongest predictor of progressive coronary artery 
disease, OR 19.01, p=0.03[54]. Finally, in the Diabetes and Sirolimus Eluting Stent (DIABETES) 
study, at 2-year follow-up, 50% of repeat revascularisations were as a result of progression 
in a vessel or segment remote and different from the one previously treated, a finding 
which has been confirmed by others[55, 56]. Indeed, the aforementioned PROSPECT 
study, which assessed the natural history of atherosclerosis in patients presenting with 
ACS has highlighted this very fact, with the majority of subsequent adverse cardiac events, 
particularly in DM patients arising from so-called non-culprit lesions which given their 
angiographic appearance (mean diameter stenosis 36.2 [31.1-44.2]) were presumably 
non-ischaemic at baseline [14]. 
This more rapid progression may in part explain the findings of the recent studies which 
have shown worse outcomes in DM patients despite the absence of ischaemia. 
Furthermore, it is recognised that lesions which are angiographically significant are known 
to progress faster than milder lesions[57]. Thus, despite the absence of ischaemia, an “an-
giographically significant but haemodynamically non-significant” lesion in the setting of 
rapid atherosclerosis progression in DM, may not be insignificant. Indeed, Giri et al have 
shown in a study of 4755 patients undergoing SPECT myocardial perfusion imaging, of 
which 929 were diabetic, that survival during the first 2 years of follow-up was identical in 
the patients with normal MPI results, irrespective of their diabetic status, however rates 
increased rapidly after 2 years in diabetics but not in non-diabetics(Figure 4)[58]. Thus, the 
absence of ischaemia, assessed either by invasive or non-invasive methods in DM patients, 
does not appear to have the same “warranty” as in non-DM patients. 
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Coronary artery disease burden and DM
Compared to non-DM patients, DM is associated with a higher incidence of coronary 
artery calcium (CAC), an anatomic marker of increased coronary artery disease burden. 
Furthermore, non-invasive studies combining CT CAC scoring and a functional assessment 
of myocardial ischaemia in the same patient, have shown that atherosclerotic burden 
despite normal ischaemia studies predicts adverse cardiac events. Furthermore, there 
exists a strong linear relationship between increasing CAC scores and future adverse 
cardiac events, with a CAC score >400 being a significant predictor, HR 3.55 (95%CI; 
1.78–7.09 p<0.001). Alternatively, those patients with normal perfusion and without CAC 
have excellent outcomes.
The Multi-Ethnic Study of Atherosclerosis (MESA) in which 6814 participants without a 
prior history of CAD underwent CT assessment to assess the incidence of CAC, showed 
that compared to non-DM patients, DM patients have double the incidence of CAC 
presence, RR 1.9 (95% CI; 1.4-2.4, p<0.01). Furthermore, DM was identified as the strongest 
risk factor for CAC progression, HR 26.8 (95%CI; 19.5 to 34.2, p<0.001). Conversely, 38% of 
DM patients had no CAC, and the absence of CAC was associated with a low annual rate 
(<1%) of CHD events (7).  Recently, Blanke et al published 5-year follow up of the prognostic 
Figure 4   Kaplan-Meier survival curves comparing the subset of diabetic and 
nondiabetic patients with normal stress MPI results
MPI denotes Myocardial Perfusion Imaging.
Reproduced with permission from Giri et al [58]
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utility of coronary CT angiography in patients with DM from the CONFIRM (Coronary CT 
Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry[59]. 
In this study, 1,823 DM were propensity-matched to 1,823 patients without DM. In the 
absence of CAD, DM patients had similar outcomes to non-DM patients, HR 1.32 (95%CI; 
0.78-2.24; p=0.30). However, strikingly patients with DM and non-obstructive (diameter 
stenosis 1-49%) and thus highly likely non-ischaemic CAD, had significantly worse 
outcomes than non-DM patients with obstructive disease (diameter stenosis>50%), both 
in terms of all-cause mortality, [HR 2.09 (95%CI; 1.43–3.06, p<0.001)] and MACE [HR 5.12 
(95%CI; 2.95–8.88, p<0.001)]. These landmark findings strongly support the concept that 
DM is associated with therapy refractive, rapidly progressive coronary atherosclerosis and 
further supports the possibility that such progression may be as a result of significant 
differences in plaque composition between DM and non-DM patients, as described in the 
PROSPECT study[11, 14, 15]. 
DM and plaque composition
Marso et al in a sub-study analysis from the PROSPECT study, have shown that DM patients 
have a significantly different composition and character of atherosclerosis than non-DM 
patients[15]. Using gray-scale and radio-frequency intravascular ultrasound, non-culprit 
lesions (NCL) in DM patients were noted to be significantly longer, had a greater plaque 
burden, a smaller lumen area, and had a greater necrotic core and a larger calcium content. 
Additionally, necrotic core and calcification were significantly greater in the NCL’s of those 
DM patients with future MACE compared to DM patients who did not have subsequent 
event. Furthermore, the use of insulin theray was also noted to be associated with a 
significantly higher incidence of NCL-MACE[14].
In an additional analysis from the PROSPECT study, Kedhi et al analysed the incidence of 
NCL-MACE in 2 propensity-matched groups according to the presence of DM and 
TCFA[60]. In this study, among DM patients, the presence of ≥1 TCFA was associated with 
higher NCL-MACE at 3 years (27.8% vs. 8.9% in patients without a TCFA, HR: 3.56; 95%: 
0.98-12.96; p=0.04). Alternatively, DM patients without a TCFA had a similar 3-year rate of 
NCL-MACE as patients without DM (8.9% vs. 8.9%; HR:1.09; 95%CI: 0.27-4.41; p=0.90). Thus 
based upon this study, there would appear to be a symbiotic relationship between 
vulnerable plaque and DM, which results in excessive adverse outcomes which does not 
occur to the same degree in non-DM patients with similar plaque.
Moreover, studies have shown that a longer duration of DM and poorer gylcaemic control 
are associated with a higher prevalence of TCFA[61, 62]. Since DM not only promotes ath-
erosclerosis progression, the greater oxidative stress and hyperglycaemia associated with 
this condition also favors plaque instability and degradation[63, 64]. Given the higher 
prevalence of TCFA in DM patients, this may account for the observed elevated risk despite 
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an apparent absence of ischaemia. The Impact of OCT-detected TCFA on major adverse 
events derived from non-ischaemic (FFR negative) atherosclerotic lesions in DM patients 
is currently being studied in the COMBINE study[65]. In this prospective multi-center, 
study, DM patients with FFR-negative lesions are clinically followed after index OCT 
assessment and compared for major adverse events based on presence or absence of 
TCFA. Interestingly, both groups will be compared with a third group of patients with 
similar angiographic lesions at baseline which were FFR positive and therefore underwent 
index revascularisation. This study will shed important light onto the impact of untreated 
TCFA in FFR negative lesions and may help to explain the poorer outcomes observed in 
these non-ischaemic lesions. 
Finally, in response to progressive atherosclerosis, negative remodelling occurs more 
frequently in DM patients compared to the typical positive remodelling seen in non-DM 
Figure 5   Time-to-event estimates of non-culprit lesion-related MACE, according to  
the presence of diabetes and/or a TCFA at 3 years in the propensity matched 
groups of patients with and without diabetes
DM denotes diabetes mellitus. TCFA denotes thin-cap fibroatheroma. HR denotes hazard ratio. CI denotes 
confidence interval. NCL denotes non-culprit lesion. MACE denotes major adverse cardiac events.
Reproduced with permission from Kedhi et al [60]
N
C
L-
M
A
C
E
 a
t 3
 y
ea
rs
 (%
) 
0 
5 
10 
15 
20 
25 
30 
35 
Time in Months 
0 6 12 18 24 30 36 
43 31 29 27 26 24 14 
39 33 33 33 31 30 19 
42 41 39 37 37 35 19 
40 37 37 36 36 36 20 
Log-Rank P= 0.02 
Number at Risk: 
DM and TCFA 
DM and No TCFA 
No DM and TCFA 
No DM and No TCFA 
27.8% 
 8.9% 
12.3% 
 5.2% 
DM and TCFA (n=43) 
DM and No TCFA (n=39) 
No DM and TCFA (n=42) 
No DM and No TCFA (n=40) 
DM and TCFA  vs.  DM and No TCFA              HR: 3.56 (95%CI: 0.98, 12.96), p = 0.04   
No DM and TCFA  vs. No DM and No TCFA   HR: 2.36 (95%CI: 0.48, 12.14), p = 0.29   
116
Chapter 7
patients[66]. This vessel shrinkage and inability to overcome continued intimal hyperplasia 
may also explain why FFR and other ischaemic tests do not appear to carry the same 
warranty. Moreover, negative remodelling has been shown to be a marker of more 
advanced atherosclerosis and more abundant TCFA distribution which may also contribute 
to the reduced guarantee[67, 68]. 
Conclusions
DM patients have more rapidly progressive coronary atherosclerosis, a higher degree of 
microvascular disease, a larger burden of coronary plaque and a significantly different 
composition of atherosclerosis compared to non-DM patients. Recent evidence has 
shown that the absence of ischaemia, detected by either non-invasive or invasive 
methods, may not carry the same “warranty” as in non-DM patients. This finding should 
make us rethink our strategy when dealing with coronary atherosclerosis in DM patients. 
The use of ischaemic assessments, intracoronary morphological imaging, as well as our 
treatment modalities need to be fine-tuned to match the specific needs of this patient 
cohort, which is clearly quite different than the non-DM population. In this endeavor 
ischaemia is only one, but clearly not the only factor to take into account. Ongoing trials 
will shed more light into this fascinating model of human atherosclerosis progression. 
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Summary of the thesis
The aim of this thesis is to address whether intracoronary assessments can lead to better 
risk stratification in patients with diabetes mellitus (DM). Specifically, I examine the use of 
invasive haemodynamics and intracoronary imaging in patients with DM and evaluate 
whether these assessments may provide some insights into the poor outcomes seen in 
these patients. 
In chapter 1, a brief introduction about the subject and the background for the thesis is 
described. DM is the most common metabolic condition worldwide, with rapidly rising 
rates expected in the years to come. Outcomes with all forms of revascularisation in DM 
patients are associated with poorer results and percutaneous coronary intervention (PCI) 
outcomes in DM patients are significantly worse compared to non-DM patients. 
Furthermore, within the subgroup of DM patients with multi-vessel disease, coronary 
artery bypass grafting (CABG) has now been shown to be superior to PCI and is (at least for 
now) the guideline recommended treatment in such patients[1]. Based upon the prac-
tice-changing results of the major FFR studies (DEFER, FAME and FAME II), in which 
FFR-guided PCI outperformed angiography-guided PCI, whether the incorporation of a 
functional assessment using FFR may result in a more judicious and potentially improved 
revascularisation strategy in DM patients remains an unanswered question[2-5]. However, 
central to the adoption of such a strategy, is the outcome of those “functionally non-sig-
nificant” lesions, which based upon a FFR>0.80 undergo deferred revascularisation. Based 
upon the aforementioned FFR studies, the outcome of these non-significant lesions 
without revascularisation is excellent and PCI of such non-ischaemic lesions is not 
beneficial in terms of prognosis/symptoms and may indeed be associated with worse 
outcomes than medical therapy alone. Nonetheless, DM patients have a unique and 
unremitting form of atherosclerosis and whether such non-significant lesions remain 
quiescent in DM patients, requires further research and is examined in this thesis.
In chapter 2, the outcomes of deferred revascularisation based upon a negative FFR 
assessment (FFR>0.80) in patients with and without DM are compared. From a total of 250 
patients (122 DM, 128 non-DM) with only FFR negative lesions and who underwent 
deferred revascularisation; DM patients had a significantly higher rate of subsequent 
target lesion failure, HR: 3.65 (95%CI:1.40-9.53, p<0.01). This was largely driven by a higher 
incidence of target lesion revascularisation (TLR), HR: 3.52 (95%CI:1.34-9.30, p=0.01), whilst 
a non-significant but numerically higher incidence of target vessel myocardial infarction 
(MI), HR: 3.34 (95%CI:0.64-17.30, p=0.15) was observed. Interestingly, non-DM patients with 
FFR negative lesions appeared to have excellent outcomes, with rates of revascularisation 
and target vessel MI, similar to that reported in the larger FFR studies (DEFER, FAME). Prior 
to this, the largest previous comparison of FFR-guided deferred revascularisation 
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comprised of only 40 DM and 96 non-DM patients, and indicated that FFR-guided 
outcomes were similar in both groups (albeit a numerically higher revascularisation rate 
was reported in DM patients)[6]. Based upon this study, it appears that caution is merited 
with FFR-guided deferred revascularisation in DM patients and may not be as safe as in 
non-DM patients. 
Chapter 3 extends the analysis of FFR-guided revascularisation in patients with DM. In this 
chapter, the outcomes in DM patients with at least one remaining FFR negative lesion are 
compared to a group of DM patients with FFR positive lesions which underwent complete 
index revascularisation. From a total of 294 patients, 205 patients with at least one 
remaining haemodynamically non-significant lesion (FFR>0.80) were identified and 
compared to 89 patients who underwent FFR-guided complete index revascularisation. 
At a follow-up of 32.6 ± 18.1 months, those patients with at least one remaining FFR 
negative lesion had a significantly higher rate of subsequent major adverse cardiac events 
(MACE), HR:2.01;(95%CI :1.21-3.33, p<0.01), driven by both safety (death/myocardial 
infarction and rehospitalisation for acute coronary syndrome) and efficacy endpoints 
(TLR). Importantly, a subgroup of patients in this study were identified as being at an 
extremely high risk of future MACE, namely those patients with a history of prior MI who 
had at least one remaining FFR negative lesion. Conversely, patients without a history of 
previous MI and negative FFR lesions had much more benign outcomes. This study further 
raises concerns about the ability of FFR alone to better guide our revascularisation strategy 
in DM patients.
In Chapter 4, I endeavor to identify those factors which may be associated with an 
increased risk of deferred lesion failure (DLF). Furthermore, this chapter assesses whether 
absolute FFR values ranging from 0.81-1.00 are associated with a gradient risk of future 
events or indeed if an alternative FFR cut off might lead to better risk stratification in these 
patients. Importantly and contrary to previous studies of all-comers, FFR absolute values 
are determined to be of no discriminatory value to predict future lesion failure. Additionally, 
it is not possible to identify an alternative FFR cut off using receiver operating curve 
analysis with an area under the curve 0.57 ± 0.06 (95%CI 0.46-0.69). Using multi-variate 
analysis, prior revascularisation, HR 2.70 (95%CI 1.21-6.01, p=0.015), insulin requiring DM, HR 
2.24 (95%CI; 1.01-4.95, p=0.046), were identified as being independent predictors of lesion 
failure. Moreover, the majority of deferred lesions which did fail (22/31, 71%) resulted in 
subsequent ACS. Thus, based upon these findings, absolute hyperaemic FFR values 
should not be incorporated into risk stratification models aimed at calculating the risk of 
DLF in FFR negative lesions in DM patients and existing models may not be as valid in DM 
patients.  
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In combination, chapters 2-4 can be viewed together as the largest examination to date 
of the outcomes of FFR guided revascularisation in a population of only DM patients and 
provide some sobering results. It appears, based upon these studies, that lesions assessed 
by FFR as non-significant in DM patients are not as quiescent as in non-DM patients. These 
results should be borne in mind when considering if “functional revascularisation” using 
tools such as the functional syntax score may be the answer to closing the gap between 
PCI and CABG in DM patients.
Chapter 5 examines the impact of intravascular ultrasound (IVUS) detected thin-cap 
fibroatheroma (TCFA) on the development of future adverse cardiac events in non-culprit 
lesions in patients presenting with acute coronary syndrome (ACS) with and without DM. 
TCFA is generally recognised as one of the hallmarks of so called “vulnerable plaque”, that 
being a coronary lesion with a large lipid content and at high of future rupture and 
thrombosis. Using data from the Providing Regional Observations Study Predictors of 
Events in the Coronary Tree (PROSPECT) study, in which gray-scale and radiofrequency 
IVUS of the left main coronary artery and the proximal 6 to 8 cm of each of the 3 major 
epicardial coronary arteries was performed, we analysed the incidence of non-culprit 
lesion (NCL) MACE in 2 propensity-matched groups according to the presence of DM and 
TCFA. Notably, we found that the 3-year total MACE rate was significantly higher in patients 
with DM versus without DM (29.4% vs. 18.8%; p=0.01), which importantly was driven by a 
higher rate of NCL-MACE in DM patients (18.7% vs. 10.4%; p=0.02) in lesions which were 
angiographically very mild at index assessment. Furthermore, in DM patients, the presence 
of ≥1 TCFA in these mild lesions was associated with a higher NCL-MACE at 3 years 
compared to patients without a TCFA (HR: 3.56), whilst those DM patients without a TCFA 
had much more benign outcomes. This study shows for the first time that the combination 
of TCFA lesions in patients with DM is associated with poor medium term outcomes and 
identifies a very high risk group of patients. Moreover, these findings from angiographical-
ly mild but otherwise high risk lesions, may explain the poor outcomes seen in FFR 
assessed non-significant lesions, as in chapters 2-4.
Chapter 6 outlines the design and rationale of the COMBINE (OCT-FFR) study. In this 
study, haemodynamic assessments using FFR and plaque morphology examination using 
optical coherence tomography (OCT) will be combined for the first time in DM patients to 
attempt to better predict outcomes in DM patients. Given the results of chapters 2-4 and 
chapter 5, whether the prospective identification of TCFA in FFR negative lesions may 
identify those plaques which are likely to result in future events is to date an unanswered 
question, one we hope to address with this study. Enrollment is well under-way with an 
expected study population of 500 required to test our hypothesis.
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Chapter 7 looks at whether ischaemia is the only factor to consider in patients with DM. 
DM patients have a unique and unremitting form of atherosclerosis, particularly when 
combined with additional risk factors and so a negative ischaemic assessment may not 
carry the same warranty as in non-DM patients. This chapter takes an in-depth look at 
those specific factors which may be responsible for the poor outcomes in DM patients 
despite the absence of detectable ischaemia. 
Future perspectives and directions: Form and Function
“It is the pervading law of all things organic and inorganic, of all things physical and 
metaphysical, of all things human and all things superhuman, of all true manifestations of 
the head, of the heart, of the soul, that the life is recognisable in its expression, that form 
ever follows function. This is the law”.
- Louis Henry Sullivan, “father of skyscrapers”
Given the results of studies such as FREEDOM and the continued worse outcomes in 
patients with DM, refinements in our risk assessments and PCI revascularisation strategies 
are required[1, 7]. Since the poor outcomes in DM patients arise not just from those treated 
segments but from residual disease which subsequently progresses; further refinements 
in stent design, polymer technology and bio-absorbable scaffolds are unlikely to level the 
playing field[8-10]. In looking towards the future, the long-standing concepts of form and 
function are likely to continue to dominate the next series of investigations and in addition 
to more aggressive medical therapy, may be the key to further improvements in patients 
with DM. 
Intracoronary imaging: Form
Following on from PROSPECT, additional studies using OCT and near infra-red spectroscopy 
(NIRS) which are designed to identify high-risk vulnerable plaque are required and may 
help to further define and refine the criteria for those vulnerable lesions likely to result in 
future events. Thus, studies such as COMBINE (OCT-FFR) may provide information as to 
whether the poorer outcomes seem in DM patients with FFR negative lesions are 
attributable to vulnerable plaque features such as TCFA and may be the key to future 
precision medicine-  the concept of tailoring treatment to an individual patient’s levels of 
risk and benefit[11]. In addition, studies such as PROSPECT II and PROSPECT ABSORB may 
also provide information regarding the role of untreated TCFA in the development of 
future adverse cardiac events and the concept of plaque passivation of high-risk lesion 
with bio-absorbable scaffolds will also be assessed in the interventional arm of this study, 
and as such the results are eagerly awaited[12].
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Microvascular assessments: Function
Whilst high-risk plaque, as identified in chapter 5, may play a significant role in explaining 
the poor outcomes in relatively mild lesions in DM patients, it is possible that numerous 
factors are involved. Indeed, microvascular dysfunction, which is more prevalent in DM 
patients, is very likely to play a significant contribution[13-16]. Whether this microvascular 
disease renders FFR invalid or less reliable is uncertain, or whether the endothelial 
dysfunction, which is at the basis of this condition, results in increased plaque instability 
and resultant events, is as yet unanswered. Studies which have combined FFR, CFR and 
IMR for a complete haemodynamic assessment have shown that those patients with FFR 
negative lesions but impaired microvascular function are at very high risk for future 
events[17, 18]. Nonetheless to date no prospective study has used this information to 
modify the revascularisation strategy in this subgroup of patients. Unfortunately, the 
treatment options for cases with discordance (FFR high, CFR low, IMR high) are limited and 
current revascularisation techniques are unlikely to make meaningful gains. Thus, in those 
patients with demonstrable microvascular dysfunction aggressive medical therapy and 
intensive gylcaemic control in DM patients are essential[19]. 
Medical therapy
The development of new proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors 
have shown great promise in markedly reducing low-density lipoprotein (LDL) levels 
beyond that achieved by high-dose statins[20, 21]. Perhaps PCSK-9 inhibition through the 
prevention of further negative vessel remodelling and the marked atherosclerosis 
progression seen in DM patients, may help to extend the warranty of negative ischaemic 
assessments in this group of high-risk patients.  The recent exciting results of the GLAGOV 
study, in which patients on statin therapy were randomized to additional PCSK-9 inhibition 
with evolocumab or placebo, has shown that in addition to a vastly improved reduction 
in LDL cholesterol levels, a significant reduction in plaque atheroma volume is achieved[22]. 
The upcoming results of the FOURIER trail are expected to confirm this potent effect of 
PCSK-9 inhibition and show for the first time a reduction in hard cardiovascular endpoints 
over the use of statin therapy alone[23]. Whilst the overall absolute reductions in plaque 
volume in the GLAGOV study were modest, it has been shown that even a little reduction 
in plaque volume may result in a large modification of plaque behavior, resulting in 
stabilisation of plaque[24]. 
Moreover, the recently published YELLOW II and OCTAVIA studies which examined the 
role of aggressive lipid therapy with high-dose statins on the morphology of non-culprit 
lipid rich plaques, have shown that using high-intensity statin therapy results in a 
significant decrease in lipid plaque components; with a reduction in the length of lipid 
plaque, maximum lipid arc angle, and an importantly an increase in fibrous cap 
thickness[25, 26]. Based upon the findings of these studies, it appears that intensive lipid 
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therapy may offer a viable therapy to convert vulnerable plaque to a more stable 
phenotype. Furthermore, given the results of these studies and the aforementioned 
GLAGOV study, the use of PCSK-9 inhibitors to convert vulnerable plaque to a safer 
substrate may offer more global and enduring protection than plaque passivation with 
focal PCI and so warrants further investigation. Finally, the role of anti-inflammatory 
medications such as angiotension-converting enzyme inhibitors (ACE-I), nitric oxide 
modulators such as sildenafil and statin therapy, which have all been shown to improve 
coronary microvascular flow require additional study in DM patients with proven 
microvascular disease[27-32]. 
Conclusions 
The present thesis has shown that: 
1. In DM patients, FFR negative lesions are not associated with the same low-risk of 
future adverse events as observed in non-DM patients.
2. DM patients with FFR positive lesions who undergo revascularisation and ischaemia 
correction have better outcomes than DM patients in whom angiographically 
significant but FFR non-significant lesions are left to medical therapy.
3. FFR negative lesions in DM patients regularly result in subsequent ACS. 
4. FFR values (ranging from 0.81-1.00) are not associated with a gradient risk as seen in 
the general population.
5. DM and high-risk plaque as identified by TCFA appear to have a synergistic relationship, 
resulting in an extremely high event rate. Alternatively, those DM patients without 
TCFA have much more benign outcomes. 
6. The combination of plaque morphology assessment in FFR negative lesions in DM 
patients may possibly offer the best opportunity to develop a “precision medicine” 
strategy in DM patients and finally improve individual outcomes in this high-risk 
group of patients.
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Samenvatting van het proefschrift
Het doel van dit proefschrift is om te onderzoeken of intra-coronaire beeldvorming kan 
leiden tot een betere risicostratificatie bij patiënten met diabetes mellitus (DM). In het 
bijzonder wordt het gebruik van invasieve intracoronaire hemodynamiek en intracoronaire 
beeldvorming geanalyseerd bij patiënten met DM en wordt geëvalueerd of deze 
beoordelingen nieuw inzicht kunnen geven in de oorzaak van de slechte klinische 
uitkomsten die bij deze patiënten worden gezien.
In hoofdstuk 1 wordt een korte introductie over het onderwerp en de achtergrond van 
het proefschrift beschreven. DM is de meest voorkomende metabole aandoening 
wereldwijd, met een te verwachten snel stijgende prevalentie in de komende jaren. De 
klinische uitkomsten van alle vormen van revascularisatie maar met name de resultaten 
van percutane coronaire interventie (PCI) bij DM-patiënten zijn aanzienlijk slechter in 
vergelijking met niet-DM patiënten. Bovendien is in de subgroep van DM-patiënten met 
meervatslijden gebleken dat CABG beter is dan PCI, en CABG is derhalve (tenminste tot op 
heden) door de ESC richtlijn de aanbevolen behandeling in geval van meervatslijden bij 
deze type patiënten [1]. Uit de resultaten van de belangrijkste FFR-studies (DEFER, FAME 
en FAME II) blijkt dat FFR-geleide PCI beter is dan angiografie-geleide PCI, echter de vraag 
is of gebruik van FFR bij DM patiënten leidt tot een betere klinische uitkomst [2-5]. Op basis 
van deze FFR studies zijn de klinische uitkomsten van niet-significante laesies (gebaseerd 
op een FFR meting >0.80) zonder revascularisatie uitstekend en PCI in dergelijke niet-isch-
emische laesies niet gunstig gebleken in termen van prognose en symptomen. PCI bij FFR 
negatieve laesies wordt geassocieerd met een slechtere klinische uitkomst dan een 
medicamenteuze therapie. 
Echter, DM-patiënten hebben een unieke vorm van atherosclerose en of dergelijke niet- 
significante laesies stabiel blijven bij DM-patiënten, wordt in dit proefschrift onderzocht.
In hoofdstuk 2 worden de uitkomsten van uitgestelde revascularisatie op basis van een 
negatieve FFR meting (FFR> 0,80) bij patiënten met en zonder DM vergeleken. Bij 
uitgestelde revascularisatie van de in totaal 250 patiënten (122 DM, 128 niet-DM) met 
alleen FFR-negatieve laesies hadden DM-patiënten een significant hogere mate van falen 
van het aangedane letsel, HR: 3,65 (95% CI: 1,40-9,53, p <0,01). Dit werd grotendeels 
bepaald door een hogere incidentie van revascularisatie van het aangedane letsel (target 
lesion revascularisation TLR), HR: 3,52 (95% CI: 1,34-9,30, p = 0,01), terwijl een niet significant 
maar numeriek hogere incidentie van myocardinfarcten (MI), HR: 3,34 (95% CI: 0,64-17,30, 
p = 0,15) werd waargenomen. Interessant genoeg bleek dat niet-DM patiënten met FFR 
negatieve laesies uitstekende klinische uitkomsten vertoonden, met percentages van re-
vascularisatie en myocardinfarcten vergelijkbaar met die gemeld in de grotere FFR studies 
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(DEFER, FAME). Voorafgaand hieraan bestond de grootste eerdere vergelijking van 
FFR-geleide uitgestelde revascularisatie uit slechts 40 DM en 96 non-DM patiënten en 
deze studie toont aan dat FFR-geleide resultaten in beide groepen gelijk zijn (hoewel er 
een numeriek hogere revascularisatie percentage werd gemeld bij DM patiënten) [6]. Op 
basis van de resultaten beschreven in dit hoofdstuk blijkt dat voorzichtigheid moet 
worden geboden bij FFR-geleide uitgestelde revascularisatie bij DM-patiënten en dit 
mogelijk niet zo veilig blijkt als bij niet-DM patiënten.
Hoofdstuk 3 beschrijft de analyse van FFR geleide revascularisatie bij patiënten met 
DM. In dit hoofdstuk worden de resultaten van DM-patiënten met ten minste één 
overgebleven FFR-negatieve letsel vergeleken met een groep DM-patiënten met 
FFR-positieve laesies die de volledige revascularisatie ten tijde van de index procedure 
hebben ondergaan. Van een totaal van 294 patiënten werden 205 patiënten met ten 
minste één overgebleven hemodynamisch niet-significant letsel (FFR> 0,80) geïdentifi-
ceerd en vergeleken met 89 patiënten die FFR-geleide complete index revascularisatie 
hebben ondergaan. Bij een follow-up van 32,6 ± 18,1 maanden hadden patiënten met ten 
minste één overgebleven FFR-negatieve laesie een significant hoger percentage van 
majeure ongewenste cardiale uitkomsten (major adverse cardiac events MACE), HR: 2,01 
(95% CI: 1,21-3,33, p <0,01); zowel eindpunten betreffende veiligheid (sterfte/myocardinfarct 
en re-hospitalisatie voor een acute coronaire syndroom) alsmede efficiëntie eindpunten 
(TLR) waren hoger. Belangrijk te vermelden is dat een subgroep van patiënten in deze 
studie geïdentificeerd werd als een zeer groot risico groep op toekomstige MACE, namelijk 
die patiënten met een voorgeschiedenis van een eerdere myocardinfarct die ten minste 
één overgebleven FFR-negatieve laesie hadden. Dit betekende ook dat patiënten zonder 
een eerder doorgemaakt myocardinfarct en negatieve FFR-letsels een veel gunstiger 
klinische uitkomst hadden. Deze studie resultaten hebben geleid tot vraagtekens of het 
uitvoeren van alleen een FFR wel afdoende is om de revascularisatie strategie in de DM 
patiënten goed te kunnen beoordelen. 
In hoofdstuk 4 wordt onderzocht of er factoren te identificeren zijn die geassocieerd zijn 
met een verhoogd risico op falen van het uitgesteld behandelen van het letsel (Deferred 
Lesion Failure DLF). Verder beoordelen we of absolute FFR waarden die variëren van 0,81 
tot 1,00 in verband staan  met een gradueel afnemend risico van toekomstige 
gebeurtenissen of zelfs een alternatief FFR-afkapwaarde kan leiden tot een betere risi-
costratificatie bij deze patiënten. Belangrijk en in tegenstelling tot eerder verrichte studies 
in alle patiëntengroepen, wordt van absolute FFR waarden bij DM-patiënten vastgesteld 
dat ze geen discriminerende waarde hebben om toekomstig falen van letsels te 
voorspellen. Bovendien is het niet mogelijk om een  alternatief FFR-afkapwaarde te 
identificeren met behulp van receiver operating curve analyse met een gebied onder de 
curve van 0,57 ± 0,06 (95% CI 0,46-0,69). Multivariate analyse toonde aan dat eerdere re-
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vascularisatie, HR 2,70 (95% CI 1,21-6,01, p = 0,015) en insuline afhankelijke DM patiënten, 
HR 2,24 (95% CI, 1,01-4,95, p = 0,046) ] onafhankelijke voorspellers bleken van falen van 
letsels. Bovendien leidde de meerderheid van deze uitgestelde revascularisaties van 
letsels die faalden (22/31, 71%) tot een ACS. Op basis van deze bevindingen concluderen 
wij dat absolute hyperemische FFR-waarden niet moeten worden opgenomen in risi-
co-stratificatiemodellen die gericht zijn op het berekenen van het risico op DLF bij 
FFR-negatieve letsels bij DM-patiënten en zijn bestaande modellen mogelijk niet bruikbaar 
in DM-patiënten.
Combinerend kunnen de hoofdstukken 2-4 samen worden gezien als het grootste 
onderzoek tot op heden naar FFR-geleide revascularisatie in een populatie van alleen 
DM-patiënten met hierbij een aantal ontnuchterende resultaten. Uit deze studies blijkt dat 
laesies die door FFR metingen worden geduid als niet significant bij DM-patiënten minder 
stabiel zijn  dan bij niet-DM-patiënten. Deze resultaten moeten zeker in overweging 
worden genomen bij het overwegen van “functionele revascularisatie” met behulp van 
tools zoals de functionele syntaxscore. 
Hoofdstuk 5 onderzoekt de impact van de door intravasculair ultrageluid (IVUS) 
gedetecteerde thin-cap fibroatheroma (TCFA) op het ontwikkelen van cardiale 
complicaties bij niet-culprit laesies bij patiënten met een acuut coronair syndroom (ACS) 
met en zonder DM. TCFA wordt algemeen erkend als één van de kenmerken van de 
zogenaamde “kwetsbare plaque”, dat is een coronaire laesie met een hoog lipidengehalte 
leidend tot een hoog risico op toekomstige plaqueruptuur en trombose. Gebruikmakend 
van de gegevens van de PROSPECT studie, waarin grijs-schaal- en radiofrequentie IVUS 
van de linker hoofdstam kransslagader en de proximale 6 tot 8 cm van elk van de 3 grote 
epicardiale kransslagaders werd uitgevoerd, analyseerden we de incidentie van non-culprit 
lesion (NCL) MACE in 2 populatiegroepen met en zonder de aanwezigheid van DM en 
TCFA. Met name vonden we dat het totale MACE-percentage na 3 jaar significant hoger 
was bij patiënten met DM in vergelijking tot patiënten zonder DM (29,4% vs 18,8%, p=0,01), 
dit werd in belangrijke mate gedreven door een hoger percentage NCL-MACE in DM 
patiënten (18,7% versus 10,4%, p = 0,02) bij letsels die angiografisch erg mild waren bij de 
indexbeoordeling. Tevens was bij DM-patiënten de aanwezigheid van ≥1 TCFA in deze 
milde laesies geassocieerd met een hogere NCL-MACE na 3 jaar vergeleken met patiënten 
zonder TCFA (HR: 3,56). Zonder aanwezige TCFA waren de aantallen NCL-MACE na 3 jaar bij 
DM-patiënten veel gunstiger. Dit is de eerste studie die aantoont dat de combinatie van 
TCFA-laesies bij patiënten met DM verband houdt met slechte resultaten op middellange 
termijn en dus een zeer hoge risicogroep van patiënten identificeert. Derhalve zouden 
deze bevindingen van angiografisch milde maar hoog risico letsels de slechte klinische 
uitkomsten mogelijk kunnen verklaren die op de FFR-gebaseerde niet significante laesies 
zijn vastgesteld, zoals beschreven in de hoofdstukken 2-4. 
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Hoofdstuk 6 beschrijft het ontwerp en de rationale van de COMBINE (OCT-FFR) studie. 
In deze studie worden hemodynamische evaluaties met behulp van FFR en plaque 
morfologisch onderzoek met behulp van optische coherentie-tomografie (OCT) voor het 
eerst gecombineerd om de resultaten in DM-patiënten mogelijk beter te kunnen 
voorspellen. Gezien de bevindingen in hoofdstukken 2-4 en hoofdstuk 5 is het tot op 
heden nog de vraag of met behulp van OCT, aanvullend aan FFR, lesies kunnen worden 
geïdentificeerd die kunnen resulteren in toekomstige cardiale events, maar dit hopen we 
te kunnen beantwoorden met deze studie. De studie inclusie gaat goed en 500 studie 
patiënten zijn in totaal nodig om deze hypothese te testen.
Hoofdstuk 7 gaat in op de vraag of ischemie de enige te overwegen factor is in de 
behandeling bij patiënten met DM. DM-patiënten hebben een unieke vorm van 
atherosclerose en met name wanneer er sprake is van meerdere risicofactoren naast de 
DM, kan dit ook wanneer er geen ischemie gedetecteerd wordt onvoldoende garantie 
geven op het ontstaan van cardiale events. In dit hoofdstuk worden de specifieke factoren 
die verantwoordelijk zijn voor de slechte resultaten bij DM patiënten  geanalyseerd bij de 
afwezigheid van detecteerbare ischemie.
Toekomstige perspectieven en richtingen: Vorm en functie
“Het is de doordringende wet van alle dingen organische en anorganische, van alle dingen 
fysieke en metafysische, van alle dingen van de mens en alle dingen bovenmenselijke, van 
alle ware manifestaties van het hoofd, van het hart, van de ziel, dat het leven herkenbaar 
is in de expressie, waarbij vorm altijd functie volgt. Dit is de wet “.
- Louis Henry Sullivan, ‘vader van wolkenkrabbers’
Gezien de resultaten van studies zoals de FREEDOM studie en de voortdurende slechte 
klinische uitkomsten bij patiënten met DM, zijn verbeteringen in onze risicobeoordelin-
gen en PCI revascularisatie strategieën nodig [1, 7]. Aangezien de slechte klinische 
uitkomsten in DM-patiënten niet alleen veroorzaakt worden door de reeds behandelde 
segmenten, maar juist ook door op andere delen van de kransslagvaten waar diffuse 
aantasting zich voordoet, lijkt alleen maar focus op verdere verfijningen in stentontwerp, 
polymeertechnologie en oplosbare stents niet het juiste antwoord te zijn [8-10]. Met het 
oog op de toekomst zullen de langdurige concepten van vorm en functie waarschijnlijk 
de volgende reeks onderzoeken blijven domineren. Toch kunnen deze ontwikkelingen 
naast een nog agressievere medicamenteuze behandeling voor DM de sleutel zijn tot 
verdere verbeteringen van de behandeling bij patiënten met DM.
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Intracoronaire beeldvorming: Vorm
Naar aanleiding van de PROSPECT studie zijn aanvullende studies met behulp van OCT en 
infrarood spectroscopie (NIRS) nodig om kwetsbare plaques met een hoog risico te 
identificeren. Hopelijk leidt dit tot het ontwikkelen van criteria om kwetbare letsels beter 
te kunnen definiëren en resulteert dit in het voorkomen van toekomstige cardiale 
events. Mogelijk kunnen studies zoals COMBINE (OCT-FFR) de vraag beantwoorden of de 
slechtere klinische uitkomsten in DM patiënten met FFR negatieve letsels te wijten zijn aan 
kwetsbare plaques met bijvoorbeeld TCFA laesies en kan het eventueel de sleutel zijn 
voor toekomstig precisie geneeskunde, voor de individuele patiënt. Daarnaast zullen 
studies zoals PROSPECT II en PROSPECT ABSORB ook informatie verstrekken over de rol 
van onbehandelde TCFA op de ontwikkeling van toekomstige cardiale events. Tevens zal 
het concept van plaque passivatie in hoog risico letsels met oplosbare stents worden 
beoordeeld in de interventie-arm van deze studie. Hoopvol wordt uitgekeken naar deze 
resultaten [12].
Microvasculaire beoordeling: Functie
Terwijl een hoog risico plaque, zoals geïdentificeerd in hoofdstuk 5, een belangrijke rol kan 
spelen in de verklaring van de slechte klinische uitkomsten bij relatief niet ernstige letsels 
in DM-patiënten, zijn er waarschijnlijk veel meer factoren bij betrokken. Een factor als mi-
crovasculaire dysfunctie wat frequenter voorkomt bij DM-patiënten, zal zeer waarschijnlijk 
een belangrijke bijdrage leveren [13-16]. Of deze microvasculaire ziekte FFR ongeldig of 
minder betrouwbaar maakt, is onzeker. Daarnaast is de vraag of endotheliale dysfunctie, 
wat op basis van deze aandoening ontstaat, resulteert in verhoogde plaque instabiliteit 
en daarmee resulterend cardiale events nog niet beantwoord. Studies die FFR, CFR en IMR 
gecombineerd hebben voor een volledige hemodynamische beoordeling hebben 
aangetoond dat de patiënten met FFR-negatieve laesies maar een verminderde microvas-
culaire functie een zeer hoog risico hebben op toekomstige cardiale events [17, 18]. Toch 
heeft geen prospectieve studie tot nu toe deze informatie gebruikt om de revascularisat-
iestrategie in deze subgroep van patiënten te wijzigen. Helaas zijn de behandelmogeli-
jkheden voor gevallen met discordante bevindingen (FFR hoog, CFR laag, IMR hoog) 
beperkt en het is onwaarschijnlijk dat de huidige revascularisatie technieken significante 
voordelen hierin zullen behalen. Bij deze patiënten met aantoonbare microvasculaire 
dysfunctie zijn agressieve medicamenteuze therapie en intensieve glycemische controle 
bij DM-patiënten essentieel [19].
Medicamenteuze therapie
De ontwikkeling van proproteïne-convertase subtilisine / kexine type 9 (PCSK-9) remmers 
heeft geleid tot een aanzienlijke reductie van LDL-niveaus, een reductie die duidelijk 
hoger is dan die door hoge doses statines konden worden bereikt [20, 21]. Wellicht kan 
PCSK-9 remming door de preventie van verdere negatieve remodelling, gezien de 
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bekende snelle atherosclerose progressie in DM patiënten, juist bij deze hoog risico groep 
helpen om cardiale events te verminderen. De recente positieve resultaten van het GLA-
GOV-onderzoek, waarbij patiënten op statine therapie werden gerandomiseerd naar 
aanvullende PCSK-9 remming met evolocumab of placebo, heeft aangetoond dat naast 
een aanzienlijk verlaging van LDL-cholesterolgehalten een significante vermindering van 
het plaque atheroom volume werd bereikt [22]. Daarnaast heeft ook de FOURIER studie 
recent aangetoond dat toevoeging van PCSK-9 remming aan statine leidde tot een 
significante afname in cardiovasculaire events [23]. Terwijl de totale absolute reducties in 
plaque volume in de GLAGOV studie bescheiden waren, is aangetoond dat zelfs een 
kleine reductie in plaque volume kan leiden tot een grote wijziging van plaque gedrag, 
wat resulteert in stabilisatie van de plaque [24].
Bovendien hebben de recent gepubliceerde YELLOW II- en OCTAVIA-studies die de rol 
van agressieve lipiden therapie met hoge dosis statines op de morfologie van niet-culprit 
lipide rijke plaques onderzochten, aangetoond dat het gebruik van hoge intensiteit statine 
therapie resulteert in een significante vermindering van lipide plaque componenten; een 
vermindering van de lengte van de lipide plaque, de maximale lipide booghoek en een 
belangrijker toename in de dikte van de fibreuze cap [25, 26]. Gebaseerd op de bevindingen van 
deze studies blijkt dat intensieve lipiden therapie van essentieel belang is om kwetsbare 
plaques om te zetten in een stabieler fenotype. Bovendien, gezien de resultaten van deze 
studies en de eerder genoemde GLAGOV-studie, kan het gebruik van PCSK-9-remmers 
om kwetsbare plaques naar een veiliger substraat om te zetten, meer blijvende 
bescherming bieden dan plaque passivatie met focale PCI en dit is zeker reden voor 
verder onderzoek. Tenslotte moet de rol van anti-inflammatoire medicijnen zoals angio-
tensie-omzettende enzymremmers (ACE-I), stikstofoxidemodulatoren zoals sildenafil en 
statine therapie, die allemaal aantoonbaar de coronaire microvasculaire stroming 
verbeteren, verder worden onderzocht in DM patiënten met bewezen microvasculaire 
ziekte [27-32].
Conclusies
Het huidige proefschrift heeft aangetoond dat:
1. In DM-patiënten, FFR negatieve letsels niet geassocieerd zijn met hetzelfde lage risico 
op toekomstige cardiale events als in niet-DM-patiënten.
2. DM patiënten met FFR positieve letsels die revascularisatie hebben ondergaan betere 
resultaten hebben dan DM patiënten waarbij angiografisch significant, maar FFR niet- 
significante letsels medicamenteus worden behandeld.
3. FFR negatieve letsels bij diabetes mellitus patiënten regelmatig leiden tot een 
toekomstig acuut coronair syndroom.
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4. FFR-waarden (variërend van 0,81-1,00) bij DM-patiënten niet zijn geassocieerd met 
een gradueel afnemend risico zoals gezien in de algemene populatie. 
5. DM en hoog risico plaques een synergistische relatie lijken te hebben, wat resulteert 
in een extreem hoge cardiale event percentage. Daarnaast hebben patiënten zonder 
TCFA een betere klinische uitkomst.
6. Plaque morfologie bepaling in FFR negatieve letsels bij DM-patiënten mogelijk kan 
bijdragen aan een “precisie geneeskunde” strategie zodat de klinische uitkomsten in 
deze hoog risico patiënten hopelijk verbeteren. 
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